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3God ernæringspraksis for kreftpasienter.
Ernæringsutredning; diagnostiske kriterier og sammenheng med overlevelse og 
helserelatert livskvalitet hos pasienter med avansert tykk- og endetarmskreft.
Avhandlingen bygger på fire studier.
Artikkel 1. Denne studien undersøker meninger til 2759 sykepleiere, 1753 sykehusleger og 
359 kliniske ernæringsfysiologer (kef) fra Skandinaviske sykehus om bruk av kef’enes 
fagkompetanse i sykehus. Sykepleiere og leger som ser kef to eller flere ganger per uke i 
motsetning til de som ser kef sjeldnere enn to ganger per uke prioriterte klinisk ernæring 
høyere i avdeling, hadde oftere internundervisning om ernæring, fant det enklere å identifisere 
underernærte pasienter og pasienter som trengte ernæringsstøtte. Studien viser at sykepleiere 
og leger som ser kef oftere enn to ganger per uke har større fokus på ernæring.
Artikkel 2. I denne studien ble ernæringsstatus til 46 kreftpasienter som ble innlagt i en 
palliativ enhet undersøkt med hjelp av objektive kriterier og skjemaet ”Subjective Global 
Assessment” (SGA). I følge de objektive kriteriene; vekttap, BMI, hudfoldtykkelse, 
armmuskelomkrets, S-Albumin og S-Pre-albumin var 28 pasienter underernært. Med SGA var 
30 pasienter vurdert som underernært. SGA hadde en sensitivitet på 96% for å påvise 
underernæring. Underernærte pasienter hadde flere spiserelaterte symptomer og spiste mindre 
matporsjoner. Vi fant at to tredjedeler av pasientene var underernært og at SGA var valid som 
metode for å undersøke ernæringsstatus blant kreftpasienter med avansert sykdom. 
Artikkel 3. Her er ulike metoder for å måle nedgang i ernæringsstatus hos 77 pasienter med 
avansert tykk- og endetarmskreft undersøkt. Videre ble metodenes evne til å predikere 
pasientenes overlevelse studert. 28 pasienter hadde sarkopeni, 32 hadde ernæringsrisiko, 26 
var underernært og 16 hadde kakeksi (CCSG) mens 41 hadde kakeksi (EPCRC). De ulike 
metodene overlappet hverandre ufullstendig. Studien viste at en stor andel av pasientene 
hadde dårlig ernæringsstatus. Det å ha kakeksi (CCSG) eller å være underernært predikerte 
kortere overlevelse.
Artikkel 4. I denne studien ble ernæringsstatus og livskvalitet undersøkt hos 50 nyhenviste 
pasienter til Kreftavdelingen for vurdering av kjemoterapi for avansert tykk- og
endetarmskreft. Pasientene hadde lavere livskvalitet sammenliknet med normalbefolkningen. 
De som var underernærte eller hadde kakeksi (EPCRC-SGA) hadde både statistisk og klinisk 
signifikant dårligere livskvalitet enn de øvrige pasientene. Etter 3 måneder økte 13 pasienter 
vekt og de forbedret flere livskvalitetsparametre. Syv pasienter tapte vekt og de forverret 
livskvaliteten signifikant, mens de pasientene som var vektstabile hadde uendret livskvalitet.
Tolking. Den høye andelen av underernæring blant pasientene indikerer at mer bør gjøres for 
å forebygge underernæring tidligere i pasientforløpet. Underernæring og kakeksi kunne ikke 
holdes i fra hverandre med de metodene som ble undersøkt. Vekttap som kriterium er for 
uspesifikt til å diagnostisere kakeksi. Det er behov for å utvikle metoder for å påvise 
nedbrytning av muskulatur som kjennetegner kakeksi. En undersøkelse av ernæringsstatus 
gjennom et pasientforløp vil kunne avdekke tidspunkter for når intervensjoner bør settes inn 
mot underernæring.
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Incidence and survival of cancer
Each year, approximately 27,500 persons get cancer and 11,000 die of cancer in Norway.1
Cancer is the second leading cause of death after coronary disease and accounts for 26 per 
cent of deaths. While the death rate of coronary heart disease has decreased during the last 
two decades, the death rate of cancer has increased over the same period. In 2010, the ratio of 
death from coronary heart disease to cancer death was 1.2, compared to 2.1 in 1991. The 
incidence rates of cancer have increased over the years since the Norwegian Cancer Registry 
began reporting in 1953 (Figure 1).2 The five-year relative survival of cancer has increased 
from 32 per cent in 1970-74 to 66 per cent in 2005-09. Between 30 to 40% of all cancer 
patients will develop metastatic disease, which in most cases is incurable. 
Figure 1. Incidence rate of cancer in Norway.
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Incidence and survival of colorectal cancer
Considering both genders together, colorectal cancer (CRC) is the most frequent malignant
disease. The incidence of CRC is increasing more in Norway than in other Nordic countries 
(Figure 2). In 2009, 2,405 new cases of carcinoma in the colon and 1,219 new cases of the 
rectum were reported. Based on TNM-classification CRC is divided into four stages (stage I, 
IIA, IIB, IIIA, IIIB, IIIC and IV). According to the earlier classification of Dukes, Dukes’ A 
represents stage I, Dukes’ B represents stage IIA and IIB, Dukes’ C represents all stage III 
and Dukes’ D stage IV of distant metastatic CRC.
Figure 2. Incidence rates of CRC in males and females in Denmark, Finland, Norway and 
Sweden.
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FOLFOX, XELOX)) or irinotecan (FLIRI). The effect of bevacizumab, a target therapy 
against the VEGF receptor will be investigated in ongoing protocols. In a subgroup of patients 
with carcinomas showing the KRAS gene of wild type, a new target therapy can be provided.
The most common side effects of combination chemotherapy are bone marrow suppression,
nausea, diarrhoea, and neurosensoric toxicity. All oxaliplatin containing regimes may give 
dysesthesia commonly occurring in the extremities and triggered by exposure to cold.
Toxicities of capecitabin are hand foot syndrome, hypertension and proteinuria. Irinotecan 
may cause diarrhoea and hair loss.3
Surgical removal of metastatic liver lesions is an increasing option. About 20% of the patients 
may be candidates for surgical interventions. Several procedures can be considered, as
resection, embolisation, radioablation or combinations of these different options.3
In conclusion, the incidence of CRC is still increasing, but more patients with CRC can be 
cured and patients with mCRC are living longer. Today novel treatment options are rapidly 
introduced in the clinic. In cancer treatment, important clinical endpoints are survival or 
progression free survival.7 For patients treated with palliative intention it is also especially
important to maintain their QoL.8-11
Nutrition decline
During recent decades weight loss in cancer patients has been considered as a challenge. It is 
most frequently observed in patients with carcinoma of the head and neck, oesophagus, 
stomach and pancreas.12-14
The frequency of weight loss in cancer patients is shown ranging from 31% in patients with 
favourable non-Hodgkin’s lymphoma up to 87% in patients with gastric cancer.15 In this study 
a total of 32% of the patients had lost more than 5% of their body weight, with the highest 
rates of weight loss in patients with lung, pancreatic and gastric cancer. Weight loss has also 
been shown to be more pronounced as the disease progresses in advanced stages.12, 16, 17 The 
prevalence of weight loss was reported in 46% of cancer patients from 17 studies including 
13,167 patients and increased to 86% during the last two weeks of life.18
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The consequences of weight loss in cancer patients have been investigated in several studies.
The results indicate increased complications after surgical procedures,19, 20 increased length of 
hospital stay,21 increased treatment toxicity,22, 23 and reduced survival.15, 22-24 In malnourished 
cancer patients it has also been shown that their immune-competent cells are reduced.25
Colorectal cancer
Weight loss, nutrition risk or malnutrition has been assessed in different settings in patients 
with CRC. In one study of 101 patients it has been described that, before start of neoadjuvant 
radiotherapy, five out of 14 with stage I/II CRC had lost >10% of their usual body weight,
whereas 61 out of 86 patients with stage III/IV CRC had lost >10% of their body weight.26 At 
the end of radiotherapy 46 out of the 86 patients with stage III/IV had lost >10% of their 
baseline body weight.
In another study investigating CRC patients prior to surgery, 35 patients out of 85 were 
malnourished as assessed by SGA, 18 patients had unintended weight loss of >10% of their 
body weight and 40 patients had lost up to 10% of their body weight.27
In a Swedish study investigating CRC patients, 39 out of 75 patients had lost body weight 
over 6 months prior to surgery.21 Six of the patients had lost between 5-10% and nine patients 
had lost >10%. During hospital stay as many as 67 of the patients had lost a mean of 4.7 
±4.4% of their body weight.
An additional study investigating the nutrition risk in 186 patients prior to surgery found 
weight loss in 102 patients (55%).28 Two different tools for nutrition risk were used. Using
NRS-2002, 39% of the patients were at risk, while 32% were at risk according to Reilly’s 
NRS. All patients had CRC of stage III/IV.
A retrospective study evaluated the prognostic significance of malnutrition defined by SGA in 
217 patients with stage III/IV CRC. All patients were treated at one Medical Centre and as 
many as 113 (52%) patients were found to be malnourished.29
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In an additional study of 781 patients with locally advanced or metastatic CRC weight loss 
was reported to occur in 246 patients (34%) before referral to an oncology unit and start of
chemotherapy.23 The magnitude of weight loss was not described.
A review of 464 patients with mCRC receiving palliative chemotherapy showed that 13% of 
the patients had lost >10% of body weight and 28% had lost between 5 and 10%.4
The SGA questionnaire was evaluated in 87 patients with various malignant neoplastic 
diseases in an Out-patients Unit. A subgroup of 31 patients had CRC.30 According to SGA, 5
out of 13 patients with CRC Dukes’ B+C, and 6 out of 18 patients with CRC Dukes’ D were 
malnourished.
Of 51 patients with advanced CRC attending a clinic for palliative treatment, 28 patients were 
malnourished according to SGA. Eighteen patients had lost >10% of their body weight during
the last 6 months.31
Overall these studies show, despite different settings and stages of the disease, a prevalence of 
weight loss in CRC patients between 41 and 71%. Studies investigating nutrition risk or 
nutritional status show a prevalence between 30 and 55% for patients to be at nutrition risk or 
malnourished.
Survival
Weight loss at diagnosis has a significant impact on survival in CRC.15, 23, 32 Without weight 
loss patients survived on average 43 weeks compared to 21 weeks for those with weight 
loss.15 Also for patients with mCRC, weight loss has a negative prognostic impact on 
survival.32, 33
Malnutrition defined by SGA has shown to be of prognostic significance for survival in 
patients with ovarian cancer,34 mCRC,29, 31 and in patients with various gastrointestinal 
carcinomas.30 Well-nourished patients have been shown to attain a significantly longer 
survival.
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The reason for the reduced survival for cancer patients that have lost weight is thought to be 
the increased toxicity of chemotherapy, resulting in a lower total dose intensity of 
chemotherapy given.22, 23
In three randomised studies the effect of improving nutritional status of cancer patients by 
parenteral nutrition has been investigated. All three studies found a prolonged survival.35-37
Quality of Life
The WHO has defined QoL as a state of complete physical, mental and social well-being, and 
not merely the absence of disease.38 The concept of QoL describes health in terms that capture 
aspects of coping, flexibility, pleasure, and independence, among others. It refers commonly 
to a broad range of physical and psychological characteristics that express a person’s 
capability and pleasure to function.39 QoL is an imprecise term that means different things to 
different people and the term is under continuing debate. One aspect is the referral to those 
things that give a person worth, meaning, purpose and satisfaction to life.40 To distinguish 
between QoL in its more general sense from the requirements of clinical medicine and trials, 
the term “health-related quality of life” (HR-QoL) is frequently used.
Assessment of QoL becomes crucial in situations in which a patient's treatment is likely to 
cause distressing symptoms or disturbances in physical functioning, work, family and social 
roles, cognition, or emotional adaption.41 EORTC developed a cancer specific health-related 
QoL, HR-QoL, questionnaire measuring functional, global health status, single- and multi-
item symptoms.42
HR-QoL is a multidimensional concept which quantifies the physical and psychosocial effects 
of an illness and its therapy.43, 44 In cancer patients, health status is well reflected on the 
measured QoL, which is largely influenced by nutritional aspects.44-46 Nutrition care should 
be integrated into overall oncology care because of its significant contribution to QoL. In 
patients with advanced colorectal cancer maintenance of HR-QoL is an important aim of 
treatment besides delaying disease progression.5 Fatigue, pain, lack of energy, weakness and 
appetite loss occurred in more than 50% of patients with incurable malignant disease in whom 
a total of 37 symptoms have been identified.18
16
Nutrition care
Proper nutrition in hospital is regarded as a human right.47 It is emphasized as an essential 
component of high quality health care with a team working to achieve this.48, 49 The Council 
of Europe’s Resolution on food and nutrition care in hospitals states that hospital 
management, physicians, pharmacists, nurses, dietitians and food service staff should work 
together in providing nutrition care.50 Cancer patients often have a significant number of 
symptoms that reduce food intake. To relieve the symptoms pharmacological options should 
be chosen on an individual basis.51 Symptom assessment followed by dietary advice and 
pharmacological prescription has been proved to reduce the overall symptoms in patients with 
advanced cancer.52
Nutrition care is defined as interventions and counselling of individuals on appropriate 
nutrition intake through the integration of information from the nutrition assessment.53 In all, 
44 tools for assessing nutritional status or identifying a person at risk of malnutrition are 
identified in the literature.54 A validation of the tools for nutrition assessment is essential.55-57
The screening tools developed for adults have been evaluated for validity, reliability, 
sensitivity and specificity, ease of use and cost-effectiveness.58 Concerning outcome 
measurement, the American Society of Parenteral and Enteral Nutrition (ASPEN) stated in 
their guidelines from 2002 that only SGA had been validated with respect to clinical 
outcome.58
When different assessment tools are compared in the same group of patients, wide 
discrepancies are found in the prevalence of malnutrition.59-63 Due to the lack of a gold-
standard for nutrition assessment, a number of different tools are used. Diverse clinical 
outcomes such as the patients’ mortality, survival, physiological measure, QoL or other 
clinical end-point should be assessed when evaluating the assessment tools.64-66
The nutrition care process (NCP) was introduced by the American Dietetic Association 
(ADA) in 2003 and updated in 2008.48, 67, 68 The NCP aims to provide high-quality nutrition 
care, implicating doing the right thing at the right time, in the right way for the right person to
provide the best possible results. The NCP consists of four distinct steps; (1) nutrition 
assessment, (2) nutrition diagnosis, (3) nutrition intervention, and (4) nutrition monitoring and 
evaluation (Figure 4).
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Outcome 
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Figure 4. The nutrition care process.
Screening and Nutrition Assessment
Nutrition screening intends to identify patients at risk of nutrition deficit before it progresses
to malnutrition.69 The nutrition screening tool should be rapid to use, easy and sensitive.70
Malnutrition is both under-recognised and under-treated.71 Internationally there is an 
agreement that nutrition screening is essential for identifying those patients needing 
appropriate nutrition assessment and intervention.72-76 Early identification of nutrition deficit 
allows for early intervention and may improve clinical outcomes.70 In patients with advanced 
cancer nutrition intervention may at best only achieve weight stabilisation, suggesting early 
intervention is more beneficial to the patient.77
18
Best practice, as stated by NICE Guidelines requires that patients shown to be at nutrition risk 
should undergo nutrition assessment and be considered for treatment.78 Nutrition assessment 
is a comprehensive evaluation completed by the clinical dietitian or health care professional 
with a speciality in nutrition and includes:
i. Food/Nutrition-Related History
ii. Anthropometric Measurements
iii. Biochemical Data, Medical Tests, and Procedures
iv. Nutrition-Focused Physical Findings
v. Client History
A complete nutrition assessment usually gathers information obtained by different health care 
professionals such as physicians, nurses, speech therapists as well as from biochemical and 
microbiological analyses, and is thus a multidisciplinary task.78
Sarcopenia
Loss of skeletal muscle is age-associated and termed sarcopenia.79 Sarcopenia is derived from 
the Greek words “sarx” meaning flesh and “penia” meaning poverty. In 1989 Rosenberg 
suggested naming the decline of lean body mass seen in elderly people as sarcomalacia or 
sarcopenia.80 Originally sarcopenia was described by Evans and Campbell in 1993.81
Sarcopenia was associated with decreased muscle strength and functional capacity in elderly 
people.82 The diagnosis of sarcopenia is generally based on a combination of percentage of 
muscle mass > 2 standard deviations below the mean obtained in a reference population plus 
walking speed below 0.8 m/s in the 4-m walking test.83 Several conditions other than aging 
may lead to the development of sarcopenia, namely immobilisation, nutrition deficiencies of 
protein and vitamin D, malabsorption, endocrine disorders and cachexia.79
Computed tomography (CT) and magnetic resonance imaging (MRI) are considered to be the 
most accurate imaging methods available for in vivo quantification of skeletal muscle.84 In
1979 CT was introduced for quantifying undernutrition in hospitalised patients.85 The use of 
CT for diagnostic purpose in cancer patients has raised the possibility of measuring muscle 
mass in this population.84, 86-93
Skeletal muscle components consistent with sarcopenia may be assessed by mid upper-arm 
muscle area by anthropometry, appendicular skeletal muscle index determined by Dual-
energy X-ray Absorptiometry (DXA) or whole body fat-free mass index without bone 
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determined by bioelectrical impedance.94 As a general rule the cut-off value for muscle mass 
is set below the 5th percentile.
Malnutrition
Malnutrition literally means bad nutrition. Generally there is no accepted definition of 
malnutrition. The term is used variously, and encompasses both undernutrition, overnutrition 
and imbalance in macronutrients and micronutrients.13 Most commonly, malnutrition is 
denoted as undernutrition. The following definition of malnutrition is proposed of The British 
Association for Parenteral and Enteral Nutrition (BAPEN);
“Malnutrition is a state of nutrition in which a deficiency or excess (or imbalance) 
of energy, protein, and other nutrients causes measurable adverse effects on 
tissue/body form (body shape, size and composition) and function, and clinical 
outcome.”
The American Dietetic Association defines malnutrition as: 
“Inadequate intake of protein and/or energy over prolonged periods of time 
resulting in loss of fat stores and/or muscle wasting including starvation-related 
malnutrition, chronic disease-related malnutrition and acute disease or injury-
related malnutrition.”
Some authors also highlight the defective assimilation of food in the definition of 
malnutrition.95, 96 The malnutrition/undernutrition concept therefore comprises food intake, 
digestion and nutrient requirement.
The criteria used to define malnutrition in malignancy vary widely and make comparison 
between studies difficult and may underestimate the size of the problem. In a cohort of 5,628 
patients with neoplastic malignant disease, 7% of the patients were classified as malnourished 
based solely on BMI <20.97
Cachexia
The term cachexia is derived from the Greek words kakòs (bad) and héxis (condition). As 
long ago as 400 BC, Hippocrates wrote “the flesh is consumed and becomes water,… the 
abdomen fills with water, the feet and legs swell, the shoulders, clavicles, chest, and thighs 
melt away… The illness is fatal.”98 Cachexia is associated with several chronic diseases and 
accounts for about 20% of cancer deaths.99 Patients suffering from cachexia lose lean body 
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mass, predominantly skeletal muscles, resulting in weakness and immobilisation. Cachexia is 
not solely a nutrition deficit, but a catabolic condition with complex metabolic changes 
leading to loss of adipose tissue and skeletal muscle.100 Adipose tissue wasting is not as well 
established as loss of skeletal muscle. The importance of agreement about definition and 
classification of cancer cachexia is warranted and underlined in several publications.101-104
In 2007, a cachexia consensus working group met and agreed upon the following definition of 
cachexia;
“Cachexia, is a complex metabolic syndrome associated with underlying illness 
and characterised by loss of muscle with or without loss of fat mass. The 
prominent clinical feature of cachexia is weight loss in adults (corrected for fluid 
retention) or growth failure in children (excluding endocrine disorders). Anorexia, 
inflammation, insulin resistance and increased muscle protein breakdown are 
frequently associated with cachexia. Cachexia is distinct from starvation, age-
related loss of muscle mass, primary depression, malabsorption, and 
hyperthyroidism and is associated with increased morbidity”.101
The group recommended the following diagnostic criteria for cachexia:
Weight loss of at least 5% in 12 months or less in the presence of underlying illness, 
PLUS THREE of the following criteria:
I. Decreased muscle strength (lowest tertile)
II. Fatigue
III. Anorexia
IV. Low fat-free mass index
V. Abnormal biochemistry
a) Increased inflammatory markers C-reactive protein (CRP) >5.0 mg/L, 
Interleukin-6 >4.0 pg/ml
b) Anaemia (Haemoglobin <12 g/dl)
c) Low serum albumin (<3.2 g/dl)
Based on a study of 170 weight-losing patients with advanced pancreatic cancer, the Cancer 
Cachexia Study Group (CCSG) proposed on that cancer cachexia is characterized by three
main factors: body ZHLJKWORVVQXWULHQWLQWDNH,500 kcal/day, and a level of CRP 
mg/L.105 Patients defined with cachexia according to these criteria had a shorter survival than 
patients without cachexia.
Later on, the SCRINIO (Screening Nutritional Risk in Oncology) Working Group106 proposed 
a definition of cancer cachexia as follows:
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“cachexia is a complex syndrome characterized by a severe, chronic, 
unintentional and progressive weight loss, which is poorly responsive to the usual 
nutritional support, and may be associated with anorexia, asthenia and early 
satiation” 
They proposed also a classification of precachexia and cachexia based on the absence or 
presence of weight loss >10%, anorexia, fatigue and early satiation.
Further, a group of experts in clinical cancer cachexia research took part in a consensus 
process involving two focus groups and two Delphi rounds ending up with the following 
definition of cancer cachexia, published in 2011;94
“cancer cachexia is defined as a multifactorial syndrome characterised by an 
ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot 
be fully reversed by conventional nutritional support and leads to progressive 
functional impairment.” 
Cancer cachexia was divided into three stages; precachexia, cachexia and refractory cachexia.
At present there is no method described to identify precachexia. The criteria for cachexia were
weight loss >5% over the past 6 months (in absence of simple starvation); or BMI <20 and 
any degree of weight loss >2%; or an appendicular skeletal muscle index consistent with 
sarcopenia and any degree of weight loss >2%. 
Simple starvation in the general meaning is frequently defined as secondary nutrition impact 
symptoms or as secondary cachexia. It involves all causes of reduced dietary intake that can 
be corrected.107, 108 Studies that examine the relationship between interventions toward 
nutrition impact symptoms and nutritional status are limited. One study of the prevalence of 
nutrition impact symptoms and their relationship to QoL and performance status highlights 
the importance of early identification and management of nutrition impact symptoms in order 
to provide optimal care for patients with cancer.109
To distinguish between malnutrition and cachexia is challenging. Both declines appear with 
loss of body weight and wasting.  Malnutrition is proposed as reversible when adequate 
amounts of nutrients are provided; while cachexia is not treatable by this approach.98
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Nutrition Diagnoses
Setting nutrition diagnoses challenges the clinical dietitian to critically consider the likely 
cause(s) of the nutrition problem and how it can be solved.67, 110 Initially 62 nutrition
diagnostic terms were identified for the dietetics’ profession.111 Later on, two diagnoses were
deleted, namely hypermetabolism and hypometabolism. The reason for this was that dietetic 
practitioners are unable to treat these patients within their scope of practice. Of the 60
nutrition diagnostic terms, 22 commonly occurring diagnoses in oncological patients were
content validated by members of the Oncology Nutrition Dietetic Practice group.111 The 
diagnoses are divided into three domains; 1) Intake domain, 11 diagnoses, 2) Clinical domain, 
six diagnoses, and 3) Behavioural-Environmental domain, five diagnoses. Malnutrition 
belongs to the intake domain while unintended weight loss is one of the diagnoses in the 
clinical domain. Further, increased energy expenditure is one of the 60 diagnoses in the NCP 
but not incorporated into the terms validated by the Oncology Nutrition Practice Group.
Nutrition Intervention
Nutrition intervention is defined as “a purposefully planned action(s) designed with the intent 
of changing nutrition-related behaviour, risk factor, environmental condition, or aspect of 
health status”. The nutrition intervention is typically directed towards resolving the nutrition 
diagnoses but may also be targeted at reducing the signs or symptoms of the nutrition 
diagnoses.110 Ideally, the nutrition support should involve a team approach including clinical 
dietitians, nurses and physicians.112
Nutrition: Monitoring and Evaluation
The purpose of monitoring and evaluation is to determine if progress has been made and the 
goal(s) or desired outcome of nutrition care has been met. Monitoring and evaluation require 
active commitment to measure and record outcome indicators relevant for the nutrition 
diagnosis and intervention. The major goal of outcome management is to utilize collected data 
to further improve the quality of nutrition care rendered.
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Recently the International Confederation of Dietetic Associations (ICDA) and the European 
Federation of the Associations of Dietitians (EFAD) decided to recommend their members to
implement the NCP and the International Dietetics & Nutrition Terminology (IDNT) within 
the clinical dietitian professions.113
In conclusion, the NCP is a systematic problem-solving method developed to reflect current 
practice. The model intends to be used by food and nutrition professionals delivering nutrition 
care. The NCP is regularly reviewed and updated.
The Role of the Clinical Dietitian
According to the Council of Europe, clinical dietitians should assume a more central role in 
nutrition support.50 In 2010, the Norwegian Directorate of Health published guidelines for 
palliation in oncology where among others competence requirements for clinical dietitians
were set.114 According to these guidelines, the clinical dietitian requires not only basic 
knowledge in oncology and nutrition care, but also knowledge about evidence based diet 
therapy. The clinical dietitian has to interact in the multidisciplinary team when decisions are 
made with focus on enteral or parenteral nutrition. Another issue for the dietitian is to initiate 
research. In all, these tasks require knowledge in several areas, including palliation, 
psychosocial behaviour and communication. Knowledge in ethics is of particular importance 
when deciding to give or not to give artificial nutrition support to patients with advanced 
cancer.115 Use of enteral and parenteral nutrition in palliative care is controversial. It is mainly 
recommended in patients with a dysfunctional gastrointestinal tract to avoid dying of 
starvation.116, 117 However, it has recently been described that home parenteral nutrition 
among patients enrolled in palliative home care services was used to supplement oral intake
and not only in patients with dysfunctional gastrointestinal tract.118
One particular challenge for the majority of clinical dietitians working in hospital within 
several specialities is to gain sufficient experience to become professional and reliable.
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“I met the wee dietician, but sure the stuff was for them you know, wanting to lose 
weight. Well I, said to her about that, [that] I was losing the weight and she said ‘Oh 
well’ she says, ‘you don’t have to stick to that diet, you don’t need a diet’. You know, 
she was a young girl, you know, although well I’m saying to you she was a young 
girl, maybe she was a real dietician, you know I’m not taking that away from her… 
but this business of the weight loss, it’s a rare commodity that anybody knows all 
about it.”119
The above statement describes the experience of a patient referred to a clinical dietitian for 
counselling. Being an effective counsellor involves nutrition knowledge and good 
communication skills but also the ability to develop a therapeutic relationship with the 
patients where exchange of information and dialogue is approached.120, 121 As shown in one
study, patients and their families wanted the weight loss acknowledged and information about 
why it was happening.119 Their experience of weight loss and its impact on everyday life
emphasises that more attention has to be paid to it in order to break the taboo that exists in 
clinical practice.122, 123 When health carers avoid initiating discussion about symptoms in their 
belief that little could be done to help patients with weight loss, new approaches within this
field have to be found.123
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Aims of the Thesis
During the last two decades malnutrition in cancer patients has been of growing interest. The 
aetiology of malnutrition is complex. Today, there exists an increasing bulk of knowledge that 
nutrition interventions are beneficial in cancer patients. The overall goal within nutrition
oncology is to prevent malnutrition.
Several conditions can influence the outcome of reaching this goal;
» Of major importance can be the health care system, responsible for focussing on the field of  
malnutrition.
» Applying different methods for assessing nutritional status and cachexia, not appropriately
validated, can contribute to being unsuccessful in this context.
Therefore, the fundamental aims of this study were to obtain further knowledge about  
x the focus of health care workers on clinical nutrition
x the criteria for assessing the patients nutritional status 
x which methods classify patients with malnutrition and cachexia most appropriately
with regards to clinical outcome.
The specific aims were
1. to investigate whether doctors and nurses on hospital units with greater access to clinical 
dietitians had a better awareness and focus on clinical nutrition (Paper I)
2. to describe the nutritional status of a group of patients with different types of advanced 
malignant neoplastic diseases in a palliative unit, and to validate the SGA questionnaire in 
these patients (Paper II)
3. to investigate the prevalence of nutritionally depleted patients by different nutrition
assessment criteria in a cohort of patients with mCRC, and to examine whether the results 
obtained correlate with the overall survival and QoL (Paper III and IV)
4. to investigate the association between body weight changes and QoL after a follow-up
period of three months (Paper IV)
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Materials and Methods
Study populations and design are shown in Table 1.
Table 1. Study population
Paper I Paper II Paper III Paper IV
Population
(N)
12,678 health care 
professionals
(physicians/nurses
/dietitians)
80 patients with 
miscellaneous 
malignant 
neoplasm of 
advanced stages
77 patients with
mCRC
152 patients 
with mCRC
Setting Working in 
Scandinavian 
Hospitals
Palliative in-
patients ward
Oncology out-
patients clinic
Oncology out-
patients clinic
Country/
places
Denmark, 
Norway, Sweden
Trondheim Edmonton,
Trondheim
Trondheim
Included (N) 4,871
(1,753 / 2,759 / 
359)
46 Edmonton: 27 
Trondheim: 50
50
Design A questionnaire 
based cohort 
study
A consecutive 
prospective study
A prospective 
cohort study
A prospective
cohort study
Reference Populations
The reference data on QoL was obtained from a randomly selected population of Norwegians 
above 18 years.124 A newer publication has shown that HR-QoL in the general Norwegian 
population appears to be stable over the 8 year period from 1996 to 2004.125 The latter 
publication separated results by gender. For that reason the reference data from 1996 have
been used.
The cohort of 50 mCRC patients included in Trondheim has been compared with a total of 
760 mCRC patients referred to their first oncological consultation between 2003 and 2006 at 
three different hospitals in Scandinavia, namely Odense University Hospital in Denmark, 
Haukeland University Hospital in Norway and Uppsala University Hospital in Sweden.4 The 
reference patients revealed an unselected patient cohort considered for palliative therapy.
Terminally ill patients, older patients and those with low performance status may not have 
been referred for oncological consideration.
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Methods
Dietary Intake
A dietary history was performed in one study (Paper 2). The patients were asked to describe 
their meal pattern, to quantify their meals in household terms and describe their food choice 
with emphasis on food of high or low energy content. The dietary intake was dichotomized as
“frequent meals” defined as four meals or more, and “few meals” defined as three meals or 
less.
A dietary record was performed for four days (Norwegian population) and three days 
(Canadian population) in two studies (Paper III and IV). Food and beverages were recorded 
over consecutive days, including one weekend day. The quantity of food and beverages was 
described in household measures. Diet records were reviewed by a registered dietitian for 
completeness and were analyzed using the FoodProcessorII nutrient analysis software 
(ESHA Research, Salem OR) in the Canadian cohort. In the Norwegian cohort the diet record 
was not reviewed for completeness. The energy intake was calculated by means of the 
software Diet 32 using the Norwegian National Food Composition Tables.
CT Image
CT images distinguish different tissue types in vivo based on attenuation characteristics.126
Attenuation is a function of tissue density and chemical composition i.e. the electron per unit 
mass.127 Tissue is mainly made up of carbon, nitrogen, oxygen, and hydrogen. The ratio of 
electron-to-mass for carbon, nitrogen and oxygen is 0.5, whereas the ratio for hydrogen is 1.0.
Thus, the higher quantity of hydrogen in adipose tissue separates it clearly from other types of 
tissue and fluids. The attenuation values determined by CT are expressed in Hounsfield units 
(HU), based on a linear scale using water as reference (0 HU). CT distinguishes fat from 
muscle because fat displays negative attenuation values (-190 to -30 HU), while the 
attenuation values for muscle are within the range of -29 to +150 HU.128 On the image, the 
adipose tissue is indicated by a darker area and the muscle by a lighter area. The cross-
sectional area (cm2) of the skeletal muscle can thus be calculated from a single CT image.89
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offs were set at 52.4 cm2/m2 for men and 38.5 cm2/m2 for women. These cut-off levels are 
somewhat lower than the reference cut-off values (55.4 cm2/m2 for men and 38.9 cm2/m2 for 
women)89 derived from the New Mexico Elder Health Survey130 used in other studies.93, 131
(Source: http://www.mhhe.com/biosci/ap/seeleyap/student/olc2/CTMRIImages.ppt#274,19,Section 19)
Figure 6. CT image at the L3 level.
NRS-2002
The NRS-2002 is a system for screening of nutrition risk taking into consideration degrees of 
severity of disease and undernutrition.132 The patients are scored according to each of the two 
components whether they are absent (score 0), mild (score 1), moderate (score 2) or severe
(score 3). Finally one score for age >70 is added, giving a total score between 0 and 7. The 
screening system was validated in RCTs. The main goal was to find out whether NRS could 
distinguish between patients with positive clinical outcome and patients without an effect on
clinical outcome. Of a total of 128 RCTs thirty studies were performed in cancer patients. The 
NRS-2002 is recommended by the European Society for Clinical Nutrition and Metabolism  
(ESPEN) in the hospital setting.69 Cancer patients in general are given the score of 1 for 
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severity of disease while patients with haematologic malignant disease are given the score of
2.
SGA
The SGA is an assessment of nutritional status classifying patients in groups to be well-
nourished (SGA-A), moderately or suspected malnourished (SGA-B) or severely 
malnourished (SGA-C).133 SGA have been translated into various languages. A scored 
patient-generated version (PG-SGA) has been developed were the patients fill in weight 
history, food intake, symptoms and activities. The health care professionals classify the 
disease, metabolic demand, physical examination and make the global scoring. The PG-SGA 
has been evaluated against SGA and had been found to have a sensitivity of 98% and a 
specificity of 82% in predicting SGA classification.134
The SGA was translated to Norwegian from a Swedish version which has been translated 
from English to Swedish, back-translated and retranslated again.30 The Norwegian SGA 
questionnaire was used for the Norwegian patients in Paper 2, 3 and 4. The form was filled in 
by the clinical dietitian. The Canadian patients filled in the 1st page of the PG-SGA 
questionnaire. 
The categorization in SGA classes was done as follows: Well-nourished implied stable body 
weight or increasing body weight and “no problems with eating” while Malnourished implied 
weight loss and decrease in nutrient intake with presence of nutrition impact symptoms.
Cachexia
The criteria set for cachexia by CCSG and EPCRC were a part of the baseline characteristics 
allowing characterisation of cachexia in the patients with mCRC included in the two studies.
The association with respect to patients’ survival and QoL was investigated.
Cachexia (CCSG)
Cachexia (CCSG) was defined as present when two of the following factors were fulfilled:
CRP >10 mg/L, body weight loss >10% or energy intake <1500 kcal/d.105
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Cachexia (EPCRC)
Cachexia (EPCRC) was defined as present when the patients either showed a weight loss >5% 
during the last 6 months, or a weight loss 2% - 5% in combination with a BMI <20, or a 
weight loss of 2% - 5%, together with the presence of sarcopenia.94 Sarcopenia was defined 
using the cut-off point for the lumbar skeletal muscle index calculated from CT images.86
Cachexia (EPCRC-SGA)
The analyses in Paper 3 revealed a high proportion of the patients as having cachexia 
(EPCRC) at the same time as a high proportion of them were defined as well-nourished by 
SGA. This caused the idea of further defining cachexia (EPCRC) and only including those 
patients having ongoing weight loss. Cachexia (EPCRC-SGA) was therefore defined as 
present when patients fulfilled the criteria of cachexia (EPCRC) as well as being 
malnourished by SGA.
EORTC QLQ-C30
The EORTC QLQ-C30 is a 30-item questionnaire validated as reliable and a valid measure of 
QoL of cancer patients in multicultural clinical settings.42 The 28 items measuring physical, 
role, emotional, cognitive, social functioning, symptoms and financial difficulties have a four-
grade scale: Not at All, A little, Quite a Bit and Very Much. The two items concerning global 
QoL have a seven-grade scale of 1 Very Poor to 7 Excellent. The item scales are transformed 
to a 0-100 grade scale (Not at All = 0, A little = 33.3, Quite a Bit = 66.6 and Very Much = 
100) (1 = 0, 2 = 16.6, 3 = 33.2 and so on to 7 = 100). For the multi-items scale the mean value 
of items was calculated. A high score on the functional scales and the QoL scale indicate a 
high level of health, whereas a high score on a single symptom or symptom scale represents a
high level of symptoms. Differences in QoL score between groups of patients with or without 
nutrition decline and changes in QoL score over time were investigated for signs of statistical 
significance or clinical importance.135
32
Statistics
SPSS was used for statistical analyses. Two-sided P-values <0.05 were considered significant. 
The level was set at 0.01 in some analyses with multiple hypotheses.
Group comparisons
Group differences were explored using Pearson’s chi-squared test and Fisher’s exact test for 
categorical variables. For numerical variables Student’s t-test and Mann-Whitney U test were 
used. Kruskal Wallis ANOVA was used when more than two groups were compared.
Survival analyses
Kaplan-Meier survival curves were used to visualise the cumulative survival percentage of 
patients with or without the different nutrition declines during 60 months follow up. The 
curves start at date of assessing nutrition status or date for CT image (Paper 3).
Regression analysis
Log-rank test
Group differences in survival time in the different nutrition decline groups were tested with 
the Log-rank test (Paper 3).
Cox proportional hazard regression
To analyze the effect of nation, age and gender on the hazard ratio for the different nutrition
declines, Cox proportional hazard regression was used (Paper 3).
Linear regression analysis, adjusted age and gender
To test whether age and gender were confounders for differences in the mean QoL scores with 
the different nutrition declines, linear regression analyses were performed (Paper 4).
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Summary of Papers
Paper I: Doctors and nurses on wards with greater access to clinical 
dietitians have better focus on clinical nutrition.
In this questionnaire based study about clinical nutrition practice in Scandinavian hospitals, 
6,000 physicians and 6,000 nurses working in hospital units where under-nutrition of patients 
was documented to be common were invited to participate. Data from 2,759 nurses, 1,753
physicians and 359 clinical dietitians were stratified according to whether the clinical 
dietitians were visiting the units “frequently” (>3 times a week) or “rarely” (<2 times a week). 
Nurses and physicians who met a clinical dietitian frequently versus those who met clinical 
dietitians rarely found it more seldom difficult to identify undernourished patients (16% vs. 
25%). They claimed more rarely to lack techniques for identifying undernourished patients 
(21% vs. 38%), and more seldom that nutrition had a low priority in their department (14% 
vs. 30%). They had more often nutrition as a component of the continuous education program 
(58% vs. 39%). Sixty percent of those who met clinical dietitians frequently stated that there 
was no shortage of clinical dietitians whereas the group who met clinical dietitians rarely 60% 
stated that there was a shortage.
Of the clinical dietitians, 28% were working within one specific specialty. Of these, 67% 
visited their collaboration units frequently. They were mainly collaborating with medical 
gastroenterology, general medicine and medical oncology, respectively. Those clinical 
dietitians visiting their collaborative units frequently also referred more undernourished 
patients and more often took part in multi-disciplinary conferences at the units. There was no 
statistical difference between the opinion on sufficient clinical dietitian resources in the units 
between those clinical dietitians visiting their collaborative units frequently or rarely. The 
percentage of dietitians that stated there were sufficient resources was 11% and 5% 
respectively (P = 0.096).
In conclusion, the present study showed that physicians and nurses meeting clinical dietitians 
>3 times a week in hospital wards had better focus on clinical nutrition.
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Paper II: Nutritional status of patients with advanced cancer: the value of 
using the subjective global assessment of nutritional status as a screening 
tool.
In this paper nutritional status was assessed in 46 patients with advanced neoplastic malignant 
diseases admitted to an in-patient palliative unit during a 3-months period. A total of 80 
patients were admitted. The reasons for exclusion were readmission (16 patients), not able to 
carry out an interview (6 patients), moribund (3 patients) and other reasons (9 patients). 
Nutritional status was assessed by using objective criteria and by means of the SGA 
questionnaire. According to the objective criteria (body weight loss, BMI, TSF, MAMC, S-
Albumin and S-Pre-albumin), 28 patients were estimated to be malnourished. By SGA, 30 
patients were assessed to be malnourished as SGA-B and SGA-C.
The SGA classes correlated significantly with all the objective nutrition variables. The SGA-
A patients showed (all results given as mean values) BMI of 28, weight loss of 4%, a TSF of 
18 mm and MAMC of 26 mm, S-Albumin of 36 g/L and S-Pre-albumin of 0.23 g/L. The 
SGA-C patients showed BMI of 19, weight loss of 26%, TSF 8 mm, MAMC of 21 mm, S-
Albumin of 31 g/L and S-Pre-albumin of 0.10 g/L. The moderately malnourished patients 
(SGA-B) showed mean values for all the objective nutrition variables in between the values 
for SGA-A and SGA-C groups. 
Distribution of patients Malnourished Well nourished Total number
SGA-B and SGA-C 27 3 30
SGA-A 1 15 16
Total number 28 18 46
The sensitivity of SGA was 96% and the specificity was 83%. 
The food intake differed between well-nourished and malnourished patients. Malnourished 
patients ate small portions more often. The mean amount of symptoms affecting food intake 
was 3.7 and the most frequent symptoms were loss of appetite followed by early satiety. 
SGA-C patients had on average 5.7 symptoms affecting dietary intake.
In conclusion, we found that two thirds of the patients assessed were malnourished. The SGA 
questionnaire seems to be valid in assessing malnutrition in patients with different kind of 
advanced malignant neoplastic diseases.
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Paper III: Nutritional status, cachexia and survival in patients with 
advanced colorectal carcinoma. Different assessment criteria for nutritional 
status provide unequal results.
In this paper, nutritional status and cachexia were assessed by different assessment criteria in 
77 patients from Norway and Canada diagnosed with CRC stage IV and referred to an 
oncology clinic for treatment with chemotherapy. The nutrition assessment methods applied 
were NRS-2002, SGA questionnaire, sarcopenia and cachexia according to definitions from 
CCSG and EPCRC.
The number of patients defined as having nutrition decline varied considerably according to 
the nutrition assessment method used. Seven patients were underweight defined by BMI <20, 
32 patients were at nutrition risk by NRS-2002, 26 patients were malnourished by SGA, 16 
patients had cachexia according to CCSG criteria and 41 patients out of 75 patients had 
cachexia according to EPCRC criteria. Sarcopenia was defined in 28 patients out of 71. The 
large variation in the number of patients defined as having nutrition decline led to an 
investigation of the overlapping results obtained by the different nutrition assessment tools. A
comparison between the results obtained by NRS-2002, SGA and cachexia (CCSG) revealed 
14 patients being at risk by NRS-2002 without being detected by the two other methods. 
Seven patients were detected by SGA only, and two patients had cachexia (CCSG) without 
being detected by NRS-2002 or SGA. Similar overlaps between cachexia (CCSG), 
malnutrition (SGA) and sarcopenia have also been found. In the cohort where CT images 
were taken within 30 days from inclusion, eight patients were defined with sarcopenia without 
being detected by the CCSG cachexia criteria or SGA.
Regarding survival as clinical outcome, patients with cachexia (CCSG) had shorter survival in 
an unadjusted analysis, HR 2.43; 95% CI 1.32 to 4.47 (P = 0.005). When adjusted for nation, 
age and gender cachexia (CCSG), HR 2.26; 95% CI 1.18 to 4.32 (P = 0.014) and malnutrition 
(SGA); HR 1.83; 95% CI 1.06 to 3.13 (P = 0.029) remained significant predictors of survival.
In conclusion, the study showed a high prevalence of sarcopenia, malnutrition and cachexia 
among patients with CRC stage IV and a lack of concordance between the nutrition
assessment tools used. A group of patients that fulfilled the CCSG cachexia criteria or had 
malnutrition (SGA) showed increased risk of death.
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Paper IV: The association of different criteria for nutritional assessment 
with health-related quality of life in patients with advanced colorectal 
carcinoma.
In this paper, nutritional status and cachexia were assessed by different assessment criteria in 
50 patients from Norway diagnosed with CRC stage IV. The assessment tools used were the 
same as in paper III but a third cachexia criterion was added, viz. the EPCRC-SGA. The 
criteria of EPCRC include weight loss >5% during the last 6 months but does not consider
weight gain prior to assessment. Therefore, a new cachexia criterion, EPCRC-SGA were 
created in which patients with newly measured weight gain or stabilisation were defined to 
have no cachexia despite overall weight loss during the last 6 months.
The number of patients defined as having nutrition decline varied considerably depending on 
the nutrition assessment method used. Twenty-five patients were at nutrition risk by NRS-
2002, 16 patients were malnourished by SGA, 14 patients had cachexia according to CCSG 
criteria, 31 patients had cachexia according to EPCRC criteria and 11 patients had cachexia 
according to EPCRC-SGA criteria. Sarcopenia was found in 10 patients out of 28.
The clinical outcome in this paper was health-related QoL. At baseline, the patients showed, 
compared to a healthy population, worse scores in physical, role, social function and global 
health status. They showed lower appetite, more constipation, diarrhoea and insomnia.
Appraised statistically, cachexia (EPCRC-SGA) and malnutrition (SGA) differentiated groups 
of patients had worse or better QoL scores on eight and seven scores. Appraised clinically, 
cachexia (EPCRS-SGA) differed on 14 scales, malnutrition (SGA) on 13 scales and cachexia 
(CCSG) on 10 scales.
At 3-months follow-up, 43 patients were alive. Of these 13 had gained >5% body weight, 7 
had lost >5% body weight and 23 had stable weight. The patients with weight gain improved 
their QoL clinically with respect to role functioning, global health status, insomnia and 
appetite, whereas constipation worsened. In patients with weight loss, QoL worsened 
clinically on physical, role, emotional and social functioning as well as on the global health 
status, on pain and dyspnoea, while diarrhoea improved. Patients with stable body weight had 
unchanged QoL scores except for clinical worsening on diarrhoea.
In conclusion, the study showed a high prevalence of nutrition decline among patients with 
CRC stage IV. A group of patients that fulfilled the EPCRC-SGA cachexia criteria or had 
malnutrition (SGA) could be distinguished with clinically significant worse QoL. After the 
follow-up period of 3 months, only seven patients showed significant loss of their body 
weight. These patients also showed a significant worsening of a number of their QoL scores.
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Discussion
The Role of the Clinical Dietitian
As shown in Figure 4 the nutritional care process starts with screening for nutritional risk and 
referral of patients at risk to nutritional assessment. Better focus on nutrition among health 
care professionals is assumed to be an important premise to start this process and to 
implement good nutritional care. In Paper I it has been found that health care workers with 
access to clinical dietitians in hospital units had better focus on clinical nutrition compared to 
those without.
Clinical dietitians have gained scientific knowledge in nutrition during their education and 
have the skills to translate this knowledge into useful dietary advice. Of the responding 
clinical dietitians in Paper I, only 28% were working within only one specific specialty and 
medical oncology was rated as the third common specialty. The majority of the clinical 
dietitians in Scandinavian Hospitals therefore work with patients with malignant neoplastic 
diagnoses as a part of several medical diagnoses they have to keep updated on. Those clinical 
dietitians working in one specific specialty visited the hospital units more often than dietitians 
working within two or more specialties. Thus enabling clinical dietitians to specialise within 
nutritional oncology may increase the awareness of nutrition care among cancer patients.
Similar results were found in a study where two thirds of a group of trainees in oncology rated 
nutritional status especially important for the patients' clinical outcome.136 As many as 95% of 
the respondents stated that nutritional intervention would play a role for the QoL in a patient 
with significant weight loss. As many as 91% assumed that nutritional intervention could 
influence the patient’s morbidity. A large number, 78%, claimed that nutritional intervention 
also influences the side effects due to anticancer treatment. Eighty percent of the trainees in 
oncology expressed uncertainty in their ability to identify patients with malnutrition.  Major 
barriers to including patients in nutritional care processes were the lack of guidelines (69%), 
knowledge (60%) and time (56%). Lack of evidence obtained by means of RCT’s was only 
looked upon as a barrier in one fifth of the respondents.
The clinical dietitian is responsible for educating other health care professions about their 
competency and to clarify their role in the management of the overall treatment of cancer 
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patients. In a questionnaire study of nurses' and doctors' understanding of cachexia and 
handling of associated symptoms, 62% and 21% of the respondents, respectively, mentioned 
referral to a dietitian as the most common management strategy for poor appetite and early 
satiety in patients with advanced malignancies.137 The clinical dietitian may in different 
clinical situations advise the patient about which food to eat. However, several distressing 
symptoms should be treated pharmacologically.51 Thus, a multidisciplinary approach seems to 
be essential. The clinical dietitian can perform nutrition assessment and support the 
multidisciplinary team with strategies to improve nutritional status. In an observational study 
of 116 elderly patients with cancer, nutrition intake was maintained in 92% of the patients 
until they died.138 The most important interventions were treatment of distressing symptoms 
as pain, constipation, nausea, vomiting and heartburn, as well as dietary adaptation suggested 
by the clinical dietitian. Combined intervention of pharmacological treatment and dietary 
counselling resulted in increased appetite and body weight in a study with a mixed group of 
cancer patients with advanced disease.139 The most common symptoms treated were early 
satiety, constipation, nausea and depression. No description of the dietary counselling was 
available in this publication.
The questionnaire study in Paper I has several limitations and the results must be interpreted 
with caution. The questionnaires were sent not only to physicians and nurses working with 
cancer patients but also to health care workers within specialties where undernutrition is 
common. It is not known how many of the respondents were seeing cancer patients regularly.
However cancer patients are treated within several specialties, not only in oncology units. It is 
likely that the respondents from medical and surgical units have experience with cancer
patients. It is not known whether the health care workers distinguish patients with malignant 
neoplastic diseases from patients with other diagnoses with regards to referral to clinical 
dietitians. Several studies published in the 1980s and 1990s have contributed to the view that 
nutritional counselling has no benefit on the nutritional status of cancer patients.140-144 A
systematic review published in 2004 claimed that there is a lack of evidence to support dietary 
advice in the management of disease-related malnutrition.145 Moreover, the questionnaire was 
not developed primarily to explore the role of the clinical dietitians and its reliability was not 
tested for that purpose. Overall, the survey gave some indications that clinical dietitians play
an important role when physicians and nurses collaborate more frequently with them. They 
found it also simpler to identify undernourished patients and experienced higher priority of 
nutrition in their department than those seeing the dietitian rarely.
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Methodological terminology 
One of the challenges during the course of this thesis was to find out which of the
methodological terminologies strictly describe the different aspects of nutritional assessment. 
Terms like cachexia, anorexia, sarcopenia, malnutrition and hypercatabolism are frequently 
used as synonyms in earlier scientific reports.103 Protein calorie malnutrition, under-nutrition,
wasting disease are other common terms. Weight loss has been used as a substitute for
cachexia, caloric deficit, starvation or dehydration.102, 146, 147 Thus, more standardised 
concepts seem to be urgently needed. They would be of great value in clinical communication 
and they would also let to describe scientific work more clear-cut.48
The importance of agreement of what cachexia is has been pointed out.137 However, 
researchers and healthcare professionals may use the assessment and management differently.
It can be difficult to develop intervention strategies to improve a clinical condition when the 
terminology is interpreted differently.
In this thesis different nutritional assessments have been explored. We have investigated a 
population of patients with regard to sarcopenia, where the patients muscle mass index has
been assessed by means of CT images. The patients’ nutritional risk has been defined by 
means of criteria set by NRS-2002. The term malnutrition has been used according to the 
SGA questionnaire, in which the patients were defined as being well-nourished, moderately 
malnourished or severely malnourished, respectively. When cachexia was examined different 
criteria for cachexia has been applied and the results were described as cachexia (CCSG), 
cachexia (EPCRC) or cachexia (EPCRC-SGA), respectively. In this thesis, the broad term 
nutritional decline implicates any of the conditions referred to as malnutrition, cachexia, 
nutritional risk or sarcopenia.
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Assessments and Clinical Outcome
Sample and Patient Characteristics
In Paper I, 6,000 physicians were randomly chosen from national databases of physicians, 
6,000 questionnaires were sent to lead nurses at the same departments as the selected 
physicians. The lead nurse was asked to complete one questionnaire and give the remaining 4-
9 questionnaires to the first nurses she/he met in the unit on a particular day. Clinical 
dietitians were found by means of companies offering nutritional supplements. In total, 678
clinical dietitians working in Scandinavian hospitals were identified. The questionnaire was 
sent to all these dietitians. The questionnaire consisted of 12 pages with 29 main questions 
and several sub-questions. The response rate of physicians, nurses and clinical dietitians were 
29%, 46% and 53%, respectively. Due to the length of the questionnaire it can be anticipated 
that those who answered were more interested in nutrition than non-responders. Non-
responders can of course introduce a study bias. A non-responder analysis was therefore 
performed among the Swedish physicians. The analysis revealed that non-responders were 
older, less interested in nutrition and found nutrition to be less relevant for their work.148 The 
results from the questionnaire study must thus be interpreted with this in mind. 
In Paper II, the patients were recruited from an in-patient palliative unit. During the 
recruitment period a total of 80 patients were admitted, only 46 of them were included in the 
study. Readmission was an exclusion criterion of 16 patients. The remaining 18 patients were 
excluded for several reasons; three were moribund, six were judged as not able to carry out an 
interview and nine patients were excluded of other reasons (psychiatric inconvenience,
aphasia, not willing, amnesia, non-native-speaking, spouse’ anxiety, intoxication). The 46 
patients included in the study could be looked upon as a strongly selected group. Thus, the 
high prevalence of nutritional decline described in the results may not be representative for a
general population of in-patients in palliative units.
The study of dietary intervention in mCRC patients was aimed at investigating the effect of 
individualised nutrition counselling according to the principle targeted nutrition care. The 
patients were randomised to dietary intervention or control. All patients were followed up 
every 3 months with assessment of body weight, bioelectrical impedance assessment, QoL 
questionnaire and diet history. The intervention group was offered consultation of the clinical 
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dietitian in between the ordinary follow-ups date. The patients were asked to call if they 
experienced weight loss. However, after the inclusion of 50 patients it was clear that control 
patients were referred to the dietary department for dietary counselling and intervention 
patients failed to make contact when their body weight declined. The inclusion was thereafter 
stopped and all patients were followed-up according to the protocol. There was no significant 
difference in the number of dietetic consultations between intervention patients and controls.
The Norwegian patients (Paper III and IV) were mainly recruited from the out-patient clinic.
The intention was to ask all patients with mCRC referred to the Oncology Clinic with mCRC
to participate in the study. However, when the patients not included in the study were checked 
further on, we found that 16 patients had not wanted to participate and 98 patients were living 
outside Trondheim. There were 38 patients living in Trondheim but it is not known how many
of them were invited to participate. Barriers to study recruitment can be patient related or 
physician related. Important areas identified for recruiting patients in RCT, are trial specific 
factors, practical considerations, patient factors and anticipated outcome.149 In cancer-related 
trials it is well-known that older adults, rural residents and individuals of low socioeconomic 
status are underrepresented.150 During the recruitment period of our study, an additional study 
of chemotherapy in mCRC patients was initiated. In fact, the patients should have been able 
to participate in both studies. However, the inclusion of patients in our study was reduced, 
maybe due to the large amount of information demanded.
Patient characteristics of our study cohort and of the 760 mCRC4 patients referred for their 
first oncological consideration at three hospitals in Scandinavia during 2003 to 2006 are
shown in Table 2. The figures can at least give some information about how representative
our small cohort is compared to a larger population with mCRC. The most striking 
differences were the number of metastases and the patients’ weight loss. Our study included 
more patients with metastases to only one site as well as more patients with weight loss 
>10%. Age, gender, performance status and site of metastases were, however, similar in the 
two cohorts. Our patients were not consecutively included, as it was in the large study. Thus, 
despite similarities in most characteristics, our cohort may not be representative for the 
general population of mCRC patients referred for oncological consideration. 
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Table 2. Patient characteristics 
N Age,
year
median
Gender,
Men
percentage
WHO 
status 0-3
percentage
Metastases,
Number
percentage
Metastases,
Sites
percentage
Weight 
loss
percentage
Trondheim
study
50 63 53 0: 40
1: 47
2: 13
3: 0
1: 65
2: 25
3+: 10
Liver  65
Lung 29
Lymph 
node   17
5-10:18
>10: 34
Scandinavian
references
760 64 53 0: 50
1: 32
2: 14
3:   3
1: 35
2:    39
3+: 26
Liver  60
Lung 28
Lymph 
node 29
5-10: 28
>10: 13
Sarcopenia in Patients with mCRC
The prevalence of sarcopenia in the patients with mCRC in our study was high; about two out 
of five patients had such decline (Table 3). Sarcopenia was found in all strata of BMI classes
except within BMI >30. Somewhat unexpectedly only two out of 23 patients with BMI >25 
were sarcopenic (Paper III). We have not found any studies solely investigating prevalence of 
sarcopenia in colorectal cancer patients in the literature. In one study >50% of the patients 
were found to be sarcopenic, but this was in a mixed group of non-small cell lung cancer and 
CRC patients.89 Another study analysing sarcopenic obesity (BMI >30) among cancer patients 
with mixed diagnoses revealed 38 patients out of 250 to be obese and sarcopenic, giving a 
prevalence of 15% for sarcopenia.86 In pancreatic cancer patients sarcopenia was found in 
56% of all investigated patients and in 41% of those with BMI >25.93 In our study we used 
the cut-off value for sarcopenia from a study where skeletal muscle index defined by means of
CT images were associated with mortality.86 These cut-off values were lower than cut-off 
values derived from DXA where the cut-off was set by two standard deviations below the 
mean of healthy people.89 Thus, the prevalence of sarcopenia found in our cohort could have 
been higher if the two standard deviation limit would have been used. Due to the small 
number of patients in our study the prevalence of sarcopenia found should not be considered 
as ultimate for patients with mCRC in general.
Interpreting the impact of having sarcopenia in mCRC patients we found the hazard ratio for 
risk of death to be 1.74 (95% CI = 0.99 to 3.03, p=0.053) after adjusting for nation, age and 
gender. It was not significant, but it can be argued that the trend was toward increased risk of 
death. Sarcopenia in overweight and obese patients has been found to be an independent
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predictor of survival among cancer patients with mixed diagnoses (hazard ratio, 4.2; 95% CI 
= 2.4 to 7.2, P<0.0001) 86 and in pancreatic cancer patients (hazard ratio, 2.1; 95% CI = 1.2 to 
3.5, P=0.006).93 Before conclusions about the influence of sarcopenia on mCRC patients 
survival can be drawn, future studies are needed.
Table 3. Results from Paper II, III and IV.
Nutrition
assessment
Number of patients having nutrition 
decline
Clinical outcomes
Survival QoL
Mixed 
cancer 
diagnoses
Colorectal cancer Colorectal cancer
N=46 N=77
Norway 
and Canada
N=50
Norway
N=77
Norway and 
Canada
N=50
Norway
Hazard 
ratio, 1)
Median 
survival 
months
Number of 
QoL scales 
differing 
statistic 
significant
Number 
of QoL 
scales 
differing 
clinical 
significant
Malnourished by 
combination of 
criteria (body 
weight loss, BMI, 
TSF, MAMC, S-
alb, S-pre-albumin
28
Sarcopenia 28 10 HR 1.74
15.3 vs. 
17.3
0 4
Nutritional risk 
(NRS-2002)
32 25 HR 1.42
15.8 vs. 
19.1
0 2
Malnourished 
(SGA)
30 26 16 HR 1.83
12.4 vs. 
19.5
7 13
Cachexia (CCSG) 16 14 HR 2.26
13.3 vs. 
21.4
3 10
Cachexia
(EPCRC)
41 31 HR 1.54
15.8 vs. 
19.5
0 5
Cachexia
(EPCRC-SGA)
11 HR 1.82, 2)
13.7 vs. 
19.1
8 14
1) adjusted for nation, age and gender, 2) not published
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Some unexpected sarcopenia did not show significant statistical separation of QoL scales.
This finding should not be overemphasised. The subgroups investigated were small with only 
28 patients totally. Appraised clinically,151 those patients having sarcopenia had lower scores 
on physical, role and social scales. We compared QoL measures with sarcopenia data 
obtained from CT images taken + 30 days from the date were the patients replied to the QoL 
questionnaire. One can not assume that the skeletal muscle mass has been unchanged in this 
period. Ideally both measures should be taken on the same day. It would reduce the bias that 
can arise from changes in body composition during the two measures.
The high prevalence of sarcopenia in our cohort of mCRC patients raises the question of 
whether there can be an association between vitamin D and sarcopenia in this population of 
patients. Low serum of 25-OH vitamin D is shown to be related to low muscle mass and low 
muscle strength.152 Results from several studies support the hypothesis that vitamin D is 
inversely related to colorectal cancer risk.153 In a recent dose-response meta-analyses, it was 
found inverse associations between dietary vitamin D and CRC risk.154 Further, in a cohort of 
515 patients with mCRC it was found that 50% of the patients were vitamin D deficient (<20 
ng/mL), and 82% were vitamin D insufficient (<30ng/mL).155 Thus, future supplementation of 
vitamin D to depleted patients would easy to be performed. A screening for vitamin D 
deficiency should also be discussed, especially in a group of CRC patients.
Nutritional risk in Patients with mCRC
The NRS-2002 identified 32 out of 77 of the mCRC patients to be at nutritional risk. We have 
not found any publication in the literature investigating the NRS-2002 in a clinically defined 
cohort of mCRC patients. One study reported nutritional risk from NRS-2002 in CRC patients 
before elective surgery to be 39%, which is a similar finding compared to ours.28
When exploring the overlaps between nutritional risk, malnutrition and cachexia (CCSG) in 
the 73 patients in the cachexia (CCSG) cohort, 14 patients were detected at nutritional risk but
they were not diagnosed as malnourished or having cachexia (CCSG). Twelve patients were 
not detected at nutritional risk but were malnourished and/or had cachexia (CCSG) (Paper 
III). NRS-2002 are suggested to be used within 48 hours after the patients hospital 
admission.63 Those patients detected by NRS-2002 having nutritional risk should be further 
assessed for malnutrition. However, if NRS-2002 doesn’t detect the malnourished patients
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found by SGA, some patients will be lost for further interventions. As the most appropriate
tool for nutritional screening that tool which best predicts clinical outcomes, has been 
proposed. When classifications of nutritional decline differ, the identification of the tool most 
effectively predicting outcome may be one useful indicator.156 However, in our cohort of 
mCRC patients, NRS-2002 did not significantly predict the patients reduced survival or worse 
QoL. Thus, NRS-2002 is not the most appropriate tool in this population of patients.
Malnutrition in Patients with mCRC
The SGA questionnaire used has been proposed on two occasions during treatment and 
follow-up. When starting chemotherapy for mCRC, one third of the patients were defined as 
malnourished. In the group of patients with miscellaneous neoplastic malignant diseases 
admitted to a palliative unit, two thirds of the patients were malnourished. The SGA 
questionnaire has been validated and interpreted as the gold-standard for nutritional 
assessment in hospital settings.63 Though it should be commented that the SGA does not 
cover the broad evaluation for nutritional assessment recommended in the NCP.
In the literature malnutrition in patients with CRC assessed by SGA has shown a prevalence 
of malnutrition between 30% and 55%,29-31 with the exception of one study where only four 
patients out of 75 were defined as malnourished (SGA B/C)21. In another investigation 29%
of newly diagnosed CRC patients were found to be malnourished.157 Further, during 
chemotherapy in a small cohort of 33 CRC patients with two third of the patients at stage IV, 
almost half of them were defined as malnourished.158 In general, the prevalence of 
malnutrition in patients with CRC is high as described in the literature. Our results 
investigating a clinically well-defined cohort of patients with mCRC showed that one third of 
them were malnourished. These findings seem to be in good concordance with the literature.
Our cohort showed more than twice the number of patients who had experienced weight loss 
>10% compared to the mCRC reference population. The intention for participating in our
study may, for some patients, have been their own experience of weight loss. Thus, the cohort 
studied could have been biased. However, the prevalence of malnutrition recently found is not 
greater than in comparable studies.
The median survival of well-nourished mCRC patients was 19.4 months compared to 12.4 
months in the malnourished patients. Two other studies have explored survival in mCRC 
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patients using the SGA. One study found a median survival of 12.8 months in well-nourished 
patients, 8.8 months in moderately malnourished and 6 months in severely malnourished 
patients.29 The second study found a median survival of 18.4 months in well-nourished and 
10.3 months in the malnourished patients.31 Overall, the significance of being well-nourished
for prolonged survival in mCRC is notable.
Separation by SGA of patients in to groups of better and worse QoL was statistically
significant on seven scores and clinically significant on 13 out of 15 scores. Thus, 
malnutrition has been found to be of great importance for QoL. A retrospective study in CRC,
where half of the patients had mCRC, found similar statistical differences in QoL scores on
global health score, role function, fatigue, pain, insomnia, and appetite loss.159 Twenty six 
percent of the variation of change in QoL has been explained by changes in PG-SGA in a 
mixed group of cancer patients.160 A study made on pancreatic cancer patients showed that 
weight stabilisation over 8 weeks was associated with improved QoL.161 Not only the 
association between malnutrition and QoL has been established. There is growing evidence 
that nutritional interventions improve patients’ nutritional status and QoL. Studies has been 
undertaken on dietary counselling in CRC patients,162 in patients with mixed cancer 
diagnoses163, 164 and of supplementation of parenteral nutrition in mCRC patients.36
Cachexia in Patients with mCRC
The prevalence of cachexia (Paper III, IV) has been investigated using the diagnostic criteria 
set by CCSG and EPCRC, see above. The results showed that 16 out of the 77 patients had 
cachexia according to CCSG, whereas as many as 41 had cachexia according to EPCRC. 
It became evident that several patients had experienced weight loss, most often temporary. At 
inclusion, for 51 of the 77 patients either stable weight or recent weight gain were 
documented. These observations lead to the establishment of a new set of cachexia criteria 
where those patients with cachexia according to EPCRC but with recent weight stabilisation 
or weight gain were ultimately defined as having no cachexia. Thus, by means of the new 
cachexia criteria, entitled EPCRC-SGA, only 11 out of the 50 patients investigated were 
defined as having cachexia.
The prevalence of cachexia using these three different criteria varies threefold. The highest 
prevalence has been found using the criteria of EPCRC. Thus, it raises the question “which of 
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the definitions most accurately diagnoses cachexia?” With the lack of a gold-standard for 
diagnosing cachexia this has to be a question for future research. A recent publication 
requested universal collaboration to develop a diagnostic tool for assessing cachexia. There, 
one refer to the area of cancer pain where about 50 different tools are available.165
Cachexia (CCSG) was the tool that best distinguished patients in groups with better or worse 
overall survival. Median survival in the group without cachexia (CCSG) was 21.4 months 
compared to 13.3 months in those having cachexia (CCSG). Thus the difference in survival 
between the groups was found to be 8 months.
As well-known one main difference between cachexia (CCSG) and the other criteria of 
cachexia investigated is the inclusion of CRP. The CRP value is used as a surrogate marker 
for the assessment of cytokines. CRP is known to be synthesised in the liver in response to 
soluble cytokines, interleukin (IL)-1, IL-6, IL-11, tumour necrosis factor-Į 71)-Į DQG
transforming growth factor-ȕ7*)-ȕ166 Cytokines are mediating tissue catabolism in animal 
models. In humans their effect is more uncertain.99 CRP elevation is found to be of prognostic 
significance in CRC patients previous to elective tumour surgery,167-173 in metastatic CRC
patients,32, 174 in CRC patients with peritoneal carcinomatosis,175 and in patients who are 
aimed to undergo surgical procedures of CRC liver metastases.176 The cut-off value for CRP 
elevation has in these studies has been set at different levels (CRP > 5 mg/L,32, 167, 168, 170 CRP 
> 8 mg/L,171 CRP > 10 mg/L,169, 173, 174, 176 CRP >35 mg/L.175 In one study four different strata 
of CRP levels were investigated172). CRP elevation >1.8 mg/L was in one study not found to 
demonstrate significance differences with regard to overall survival in patients undergoing 
curative resection for CRC.177 The cut-off level of CRP >10 mg/L in our study showed a 
hazard ratio, 2.56 for death; 95% CI = 1.4 to 4.6, P<0.002.
Of the three cachexia assessments investigated, the cachexia (EPCRC-SGA) differentiated 
most superior between the groups of patients with better or worse QoL. As EPCRC-SGA has 
been derived from the cachexia (EPCRC) excluding the number of patients being well-
nourished by SGA, we would expect that the number of patients identified by the two 
assessments should be nearly identical. Nevertheless, 11 patients were defined having 
cachexia (EPCRC-SGA) and five more patients were malnourished by SGA. Further, the two 
assessments identified groups of patients differing in characteristics of worse QoL, in that 
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patients with cachexia (EPCRC-SGA) scored significantly on emotional and cognitive 
function scales while the malnourished patients scored significantly on role function.
Survival
Overall survival was best predicted of having cachexia (CCSG), secondly of being 
malnourished (SGA). The two nutritional declines are partly overlapping, 12 patients had both 
declines while four patients had only cachexia (CCSG) and 13 out of 73 patients were only 
malnourished (Paper III). The two assessment tools were thus distinguishing different cohorts 
of patients and seem to be not interchangeable.
One of the specific aims of this thesis was to investigate whether the different nutritional 
decline will be able to predict survival in a clinically defined cohort of mCRC patients. In the 
literature several prognostic factors for CRC patients have been published. Negative 
prognostic factors for CRC patients are as follow; more than one metastatic site, S-albumin, 
alkaline phosphatase (ALP), lactate dehydrogenase (LDH), white blood cell count (WBC), 
reduced haemoglobin level, low energy intake, anorexia, impaired physical function, low
performance status, advanced age and low QoL.31-33, 141, 178-184 Phase angle, determined by 
bioelectrical impedance analysis, in mCRC patients has been shown to be a prognostic 
factor.185 Phase angle correlates with malnutrition (SGA) in CRC patients (stage III and IV)
and thus may be a marker of nutritional status.186 Also marital status has been shown to be of 
predictive value. Higher mortality has been found among patients who had lost their partners 
previous to surgery187 and in widowed women.188 In our study only a number of the known 
predictive factors were investigated. Our intention was not to sort out which factor finally 
should be used to predict survival in mCRC patients. Such a study has to be planned 
especially with this intention. Identification of prognostic factors is important for planning 
nutritional intervention and overall clinical management of cancer patients in general,
especially for patients in advanced stages. Our study intended to compare different diagnostic 
tools for nutritional decline in mCRC patients and to find out whether they showed an input 
on clinical outcome. For this purpose we selected survival and QoL.
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Quality of Life
We have studied the association between the patients QoL and several nutritional declines.
Both cachexia (EPCRC-SGA) and malnutrition (SGA) distinguished most superior between
groups of patients as having better or worse QoL. To maintain good QoL in patients with 
mCRC it seems to be important to know the aspects which affect QoL and be familiar with 
the relation between nutrition and QoL. Gender-associated differences in QoL in CRC 
patients were found. Women indicate more fatigue, nausea/vomiting, pain, dyspnoea, sleeping 
disturbances and appetite loss compared to men.189 High levels of distress were found among 
unmarried and male patients.190, 191 Other factors that may affect QoL in CRC patients were
depression192 and having a stoma.193
Dietary counselling in CRC patients undergoing radiotherapy increased dietary intake, 
maintained or improved nutritional status and improved all QoL function scales in a 
prospective, randomised, controlled trial.162 Single symptoms and symptom scales 
deteriorated at the end of treatment. Nevertheless, this decline was transient and after three 
months the scores were reversed to basic level. In a mixed group of patients with CRC and 
gastric cancer, the patients who managed to gain weight had a higher score for global QoL 
and lower scores for fatigue and appetite loss, while no statistical difference was seen in QoL 
scores between the randomised groups.194 A third study of nutrition intervention showed
similar results with minimising weight loss, better global QoL and physical function in 
patients receiving dietary counselling during radiotherapy for malignant tumours in the
gastrointestinal tract and the head neck area.164
Parenteral nutrition is a controversial topic and has not been established as nutrition treatment 
except when the patients suffer from a dysfunctional gastrointestinal tract and will, without 
adequate nutrition, die of starvation.195 A randomised study on mCRC patients where one 
group was supplied with parenteral nutrition containing 675 kcal/day ha shown, that these 
patients experienced less chemotherapy-related side effects such as mucositis and diarrhoea. 
They also reported fewer symptoms such as early satiety, constipation, nausea, vomiting and 
abdominal pain. QoL improved most in the parenteral group in whom a significant increase in 
appetite was seen. The energy intakes in both groups were equal.
During the 3 months follow-up we found that the majority of the patients had stable body 
weight, seven patients lost and 13 patients gained body weight. Those patients losing weight 
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had a statistically significant worsening in physical, role and social functioning while 
diarrhoea improved. The reason for the improvement of diarrhoea was not obvious, may be it 
was a side effects of chemotherapy; induced when given and improved when it was stopped. 
It has been suggested that weight gain could be a marker of tumour response to 
chemotherapy.196 On the contrary weight loss could indicate no response and ending 
chemotherapy. Another possibility is that less diarrhoea indicates dehydration of the patient.
The patients gaining body weight had clinical improvement in role functioning, global health
status, insomnia and appetite, whereas constipation worsened. In patients with stable body 
weight the QoL scores remained constant except for clinical worsening of diarrhoea. The 
improvement in QoL in the patients gaining body weight could indicate that weight gain is an
improvement in nutritional status and not merely accumulation of water.
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Conclusions and Future Directions
In the present thesis we have studied the focus of health care professionals on clinical 
nutrition, studied criteria for assessing nutritional status in cancer patients and evaluated 
methods for classifying malnutrition and cachexia regarding patients’ survival and QoL as 
clinical outcomes.
The results from the papers can be summarised as follows:
x We found an association between increased focus on clinical nutrition and frequent visits
of clinical dietitians in hospital units where undernourished patients were common. 
Physicians and nurses seeing clinical dietitians >3 times a week had a higher priority on 
nutrition, found it less difficult to identify undernourished patients and had more often 
nutrition on their educational programme.
x The frequency of malnutrition found was high (65% or two out of three) among patients 
with advanced malignant neoplastic diseases.
x Subjective global assessment of nutritional status was found to be a valid assessment tool 
for use in patients with advanced malignant neoplastic diseases. Patients have been
categorized into three distinct groups of nutritional status; well nourished, moderately 
malnourished and severely malnourished.
x Two out of five mCRC patients were diagnosed with sarcopenia.
x Two out of five mCRC patients were at nutritional risk.
x One out of three mCRC patients was malnourished.
x Cachexia was present in between one and three out of five mCRC patients depending on
the criteria used for assessing cachexia.
x The mCRC patients fulfilling the criteria for cachexia proposed by the Cancer Cachexia 
Study Group or malnourished according to (SGA) could be distinguished by a 
significantly shorter survival.
x There was overlap between cachexia (CCSG) and SGA, but four patients had cachexia 
(CCSG) without having malnutrition (SGA) and 13 patients were malnourished (SGA)
without having cachexia (CCSG). Thus both tools dispartate patients that were not 
detected by the other tools.
52
x The mCRC patients fulfilling the criteria for cachexia defined by EPCRC, and adjusted 
for weight stabilisation or weight gain, could be distinguished with significantly worse 
statistical and clinical QoL. The same was found for malnourished (SGA) mCRC patients.
x A 3 months follow-up of mCRC patients referred to an Oncology Out-patient Clinic 
revealed that a high number of the patients remained weight stable or gained body weight. 
Only a minor part of the patients lost significant body weight. These patients also showed 
significant worsening of a number of their QoL scores. The patients gaining weight had a 
moderate clinical improvement in some QoL scores (role, global health status, insomnia, 
appetite).
The high prevalence of nutritional decline found in mCRC patients entering chemotherapy 
calls for more focus on nutrition at an earlier occasion in time in the patient's course of the 
disease. There are urgent needs to agree consent on how to define cachexia and make clear 
distinctions of undernutrition. Weight loss does not discriminate cachexia from undernutrition
or vice versa. The mechanisms behind the muscle loss seen in cancer patients need to be 
explored. A longitudinal study investigating changes in body weight and body composition 
during the course of disease from initial diagnosis, during surgery, radiation and 
chemotherapy may bring more insight into the natural course of fluctuations in body 
composition. In such a study it would be crucial to measure muscle mass, muscle strength and 
include measures of physical activity, QoL and dietary intake.
In planning nutritional intervention it is essential to have an adequate diagnosis of the 
nutritional problem. Plain weight loss does not call for a particular intervention but calls for
an investigation about the causes of the weight loss and most likely for interventions targeting 
the specific problem. For that reason the clinical dietitians need to sub-specialise in nutritional 
oncology to yield good quality advice and guide patients in nutrition during the course and 
varying stages of the disease.
A more in-depth understanding of the association between symptoms and dietary intake is 
warranted. Last, but not least, more knowledge about the impact of symptom management on
dietary intake and nutritional status should be achieved.
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Abstract
Background & Aims
Different nutrition assessment tools and definitions are proposed for cancer-
associated malnutrition and wasting (cachexia).  We studied the associations 
between these assessments and overall survival in stage IV colorectal carcinoma 
patients.
Methods
Anthropometric measures, energy intake, biochemical variables, nutritional risk 
screening, assessment of malnutrition, cachexia and body composition from 
computed tomography images were analyzed, in 77 patients from Norway and 
Canada. Results were dichotomised into presence or absence of nutritional risk, 
malnutrition, cachexia and sarcopenia (low muscle mass) and associated with 
survival.
Results
Overall, 22% up to 55% of the patients had cachexia according to different cachexia 
criteria: 34% were malnourished, 42% were at nutritional risk, and 39% were 
sarcopenic. Forty-four percent of the patients did not meet criteria for any of these 
conditions. Patients with cachexia defined by Cancer Cachexia Study Group 
(CCSG) had shorter survival in an unadjusted analysis, [Hazard ratio (HR) = 2.43; 
95% confidence interval (CI) 1.32 to 4.47; P = 0.005].  After adjusting for nation, 
age and gender, cachexia (HR = 2.26; CI 1.18 to 4.32; P = 0.014) and malnutrition 
(HR = 1.83; CI 1.06 to 3.13; P = 0.029) remained significant predictors of survival.
Conclusions
Nutritional depletion in up to 55% of the patients was found. The lack of 
concordance between the results obtained by different assessment criteria was 
obvious. CCSG’s cachexia score was the best prognostic factor for overall survival.
1. Introduction
Malnutrition and weight loss is a frequent 
problem in patients with malignant neoplastic 
disease, affecting prognosis, length of hospital 
stay, health-care costs, quality of life and 
survival.1 The prevalence of malnutrition varies 
among tumour types and sites, and the stage of 
the neoplastic disease. There is, however, also a 
variation between the criteria used for assessing 
malnutrition. In fact, screening for nutritional 
risk and referral for nutrition assessment are the 
fundamental first steps in the nutritional care 
pathway.2 Identification of patients at risk of 
malnutrition allows an appropriate nutritional 
assessment and nutritional intervention with the 
aim of improving clinical outcomes and quality 
of life.3 Nonetheless, there is no consensus on 
which method to use for assessing nutritional 
status in patients with malignant neoplastic 
diseases.
The European Society for Clinical Nutrition 
and Metabolism (ESPEN) guideline 
recommendation for nutrition screening in the 
hospital setting is the Nutritional Risk Screening 
(NRS-2002).4 NRS-2002 has not yet been 
validated in cohorts of patients with advanced 
malignant neoplastic disease.  We previously 
reported that the Subjective Global Assessment 
(SGA) is a valid tool in assessing nutritional 
status in patients with advanced cancer 5 and 
several studies have confirmed this finding.6-10
Recent interest in cancer cachexia has led to 
the development of new diagnostic tools to 
better understand this syndrome. It is understood 
that the pathophysiology of cachexia-related 
weight loss in cancer patients consists of a 
mixture of reduced food intake (undernutrition) 
and abnormal metabolism, leading to muscle 
degradation.11 Recently, the Cancer Cachexia 
Study Group (CCSG) suggested to apply three 
diagnostic criteria for cancer cachexia, (weight
loss >10%, intake <1500 kcal / day, C-reactive 
protein (CRP) > 10 mg/L), incorporating the 
sign of systemic inflammation related to the 
wasting process.12 Another distinct process 
mentioned in the current literature is the wasting 
of lean body mass, particularly the loss of 
skeletal muscle, indicating cachexia in cancer 
patients. Several studies have demonstrated the 
utility of computed tomography (CT) images for 
the assessment of skeletal muscle wasting in 
cancer patients, and its association with reduced 
survival.13-15 In a recently published review from 
the European Palliative Care Research 
Collaborative (EPCRC) concerning definition 
and classification of cancer cachexia, the 
incorporation of sarcopenia as a diagnostic 
criterion of cachexia together with weight loss 
and body mass index was suggested.16
At present, with the lack of consensus on 
which method to use for assessing nutritional 
status, an evaluation of nutritional screening and 
assessment tools is urgently needed. Thus, the 
aims of the present study were
1. to investigate the prevalence of patients 
identified to be nutritionally depleted by 
different nutritional assessment criteria in a 
cohort of patients with advanced colorectal 
carcinoma, and
2. to examine whether the results obtained 
correlate with the patients’ overall survival.
2. Materials and methods
2.1. Patients
Fifty patients with stage IV colorectal cancer
referred to the Department of Oncology, 
St.Olav´s University Hospital, Trondheim, were 
invited to participate in a randomised study 
comparing dietary counselling to standard 
practice. Recruitment spanned from March, 
2004 to June, 2006. Inclusion criteria were 
histopathologically or cytodiagnostically 
confirmed adenocarcinoma of the colon and 
rectum at stage IV. Patients too confused to fill 
in the questionnaires were excluded.
At the Cross Cancer Institute, Edmonton, 
Alberta, 27 patients were recruited as part of a 
comprehensive cross-sectional evaluation in 
which nutritional, biochemical, and functional 
variables of the patients were assessed. 
Recruitment spanned from January, 2005 to 
October, 2006.  Inclusion criteria were: 
Histopathologically or cytodiagnostically 
confirmed colorectal adenocarcinoma of the 
colon and rectum at stage IV, over 18 years of 
age, and able to communicate freely in English. 
Individuals who were pregnant, had a pace-
maker, or were HIV+ were excluded.
Informed consent was obtained from all 
participants in both centers.
2.2 Clinical data
After inclusion, relevant clinical characteristics 
(age, sex, mode of diagnosis, metastatic sites, 
previous cancer treatment, and performance 
status according to the World Health 
Organization (WHO) scale) were recorded. In 
Trondheim, blood samples were analysed at the 
Biochemical laboratory, St. Olav’s Hospital, for 
haemoglobin (Hb), albumin and C-reactive 
protein (CRP). CRP was analysed by means of 
an immunoturbidimetric method, (Roche 
Diagnostics, coefficients of variance (CV) = 
2.9%). Blood samples from the Canadian cohort 
were analysed at the Alberta Provincial Clinical 
Laboratory, Edmonton, Canada. CRP was 
analysed by means of Rate Nephelometry on 
Beckman Image (CV=10%). All patients in the 
Norwegian cohort were followed up at the 
Department of Oncology clinically and with 
assessments of the nutritional status every 3 
months during 2 years from inclusion or until 
death. In Canada patients were invited to come 
back for a second nutritional assessment after 2 
months from initial visit.
2.3 Nutritional assessments
Anthropometric measurements
Patients were weighed without shoes, in light 
clothes or hospital gown, using a Seca digital 
scale, graduation 0.1 kg. Body height was 
measured to the nearest 1.0 cm with a 
mechanical wall-tape or stadiometer; graduation 
1 mm. Body mass index (BMI) was calculated 
as weight/height2 (kg/m2).
Energy intake
Patients recorded their consumption of food and 
beverages for four (Norway) or three (Canada) 
consecutive days, including one weekend day. 
The quantities of food and beverages were 
described in household measures. Energy intake 
of the Norwegian cohort was calculated by 
means of the software Diet 32 (Aivo, 
Trondheim) using the Norwegian National Food 
Composition Tables. The energy intake of the 
Canadian cohort was calculated by means of the 
FoodProcessorII nutrient analysis software 
(ESHA Research, Salem OR) using the 
Canadian Nutrient database. Energy intake (EI) 
was reported in absolute amounts (kcal), as well 
as divided by basal metabolic rate (EI/BMR) 
calculated using Harris Benedict equation, and 
per kilogram body weight (kcal/kg).
Sarcopenia
The skeletal muscle mass cross-sectional area 
(cm2) was calculated using CT images. The level 
of the third lumbar vertebra (L3) was chosen as 
standard landmark in which two consecutive 
transverse images were assessed for each 
patient. The first image selected was that in 
which both vertebral transverse processes clearly 
were visible. The muscles at the L3 level 
comprise psoas, erector spinae, quadratus 
lumborum, transversus abdominus, external and 
internal obliques, and rectus abdominus. The CT 
images were analysed by using the Slice-O-
matic software, version 4.3 (Tomovision, 
Montreal, QC). The mass of skeletal muscles 
was identified and assessed by means of the 
quantitative scale, measuring radiodensity in 
Hounsfield units (HU) with thresholds -29 to + 
150.17 The mean value of the HU in the two 
images was computed for each patient. The 
muscle mass index was calculated as skeletal 
muscle mass area (cm2)/height2 (m2). Sarcopenia 
was defined using the cut-off point for lumbar 
skeletal muscle index of <38.5 cm2/m2 for 
women and <52.5 cm2/m2 for men.13
The actual CT images were acquired for the 
purposes of routine medical care and not only 
for body composition analysis. As the dates for 
CT scan did not always coincide with the date 
for initial visit and nutritional assessment, 
comparison between sarcopenia and nutritional 
assessment was done only for patients who had 
an abdominal CT examination within 30 days of 
the initial assessment (average ± SE = 15 ± 9.7 
d).
NRS-2002
NRS-2002 consists of an initial and a final 
screening of the patients based on a score for 
impaired nutritional status (score 0 – 3), severity 
of disease (score 0 – 3) and age adjustment for 
patients aged >70 years (score 1) with a total 
maximum score of 7.18 The nutritional scores 
are: 0 = normal nutritional status, 1 = weight 
loss >5% within 3 months, or food intake of 50-
75% of the normal requirement during the 
preceding week, 2 = weight loss >5% within 2 
months or BMI 18.5 – 20.5 kg/m2 and impaired 
general condition or food intake of 25-50% of 
the normal requirement during the preceding 
week, 3 = weight loss >5% within 1 month 
(>15% in 3 months) or BMI <18.5 kg/m2, and 
impaired general condition or food intake of 0-
25% of the normal requirement during the 
preceding week. The severity of disease was for 
all patients scored to 1 due to their diagnosis of 
advanced malignant neoplastic disease.
SGA
The SGA questionnaire used in Norway was a 
modified version translated to Norwegian. The 
SGA classification is consistent with the original 
of Detsky.19 In Canada, the scored Patient-
Generated SGA (PG-SGA) was used.20 The two 
versions of the SGA questionnaires have been 
validated and the results obtained were judged 
essentially to be the same. PG-SGA had a 
sensitivity of 98% and a specificity of 82% 
when predicting the SGA classification related 
to Detsky.20 Therefore, all patients could be 
classified according to the three categories: 
SGA-A “well-nourished”, SGA-B “moderately 
malnourished” or SGA-C “severely 
malnourished”.
Cachexia
Cachexia was defined by means of two different 
classifications. The first one was based on the 
CCSG criteria, in which the patients are defined 
as suffering from cachexia when two of the 
following factors were fulfilled: CRP >10 mg/L, 
weight loss >10%, or energy intake <1500 
kcal/d.12 The second one was based on the 
criteria recently published in an EPCRC 
review.16 Here, the patients are defined as 
having cachexia, either when they show a 
weight loss >5% during the last 6 months, or, a 
weight loss 2% - 5% in combination with a BMI 
<20, or a weight loss of 2% - 5%, together with 
the presence of sarcopenia.
2.4 Statistical analyses
PASW Statistic 18 was used for the statistical 
analyses. Two-sided p-values < 0.05 were 
considered significant. In the survival analyses, 
all covariates except age were dichotomized. 
Kaplan-Meier survival curves and the Log-rank 
test were used to describe survival for the 
different nutritional status groups. In addition, 
we used Cox proportional hazards regression, 
unadjusted and adjusted for nation, age and 
gender. Patients’ survival were determined from 
the date of nutritional assessment until death or 
the censor date in the survival analysis for NRS-
2002, SGA and cachexia, in the survival 
analysis for sarcopenia from the date of CT 
image until death or the censor date. Date of 
censoring was set as the 13th of May 2009 in 
Norway and the 16th of April 2009 in Canada. 
The Mann-Whitney U test was used to analyze 
differences between BMI with or without 
sarcopenia.
2.5 Ethics
This study was approved by the Regional 
Committee of Medical Ethics at the Faculty of 
Medicine, Norwegian University of Science and 
Technology, Trondheim, and by the Alberta 
Cancer Research Ethics Committee, Edmonton, 
Alberta, Canada.
3. Results
The clinical data for all of the 77 patients are 
shown in Table 1a. There were 41 males and 36 
females with a median age of 63 years (22-85). 
Only 12 patients went through preoperative 
radiotherapy. Most of the patients, 65 out of 77, 
had been through surgical interventions. 
Metastatic tumour load was mainly found in the 
liver and 50 out of 77 patients had metastases 
only to one site. Many patients showed a high 
performance status according to WHO, and 
some patients, 10 out of 77, presented with 
performance status 2. Their good performance is 
also reflected by the fact that most of the 
patients, 66 out of 77, were considered to 
achieve chemotherapy. 
Nutritional and blood parameters for all 77 
patients are shown in Table 1b. Three patients in 
the Norwegian cohort did not answer the food 
diary. Twenty-one patients had CRP >10 mg/L.
Table 2 shows the association between the 
patients’ dichotomized baseline values obtained 
by the different nutritional assessment tools and 
their risk of death (hazard ratio). At censoring 
time May, 2009, 60 out of the 77 patients had 
died. Eight and 9 patients were alive in the 
Norwegian and in the Canadian cohort, 
respectively. Follow-up was at least 2.5 years for 
patients alive at censoring time. Median survival 
was 15.8 months in the Norwegian cohort and 
20.6 months in the Canadian cohort (p=0.15, 
Log rank test). 
The number of patients defined as having 
nutritional decline varied considerably according 
to the different nutritional assessment methods 
used. 
By means of the BMI, only 7 out of the 77 
patients were considered to be underweight. 
Twenty-five patients had lost more than 10% of 
their body weight when entering the study and 
20 of them had lost all within 6 months (not 
shown in table).
The assessment of sarcopenia, could not be 
done in six patients due to missing CT images at 
the L3 level. Of the remaining 71 patients in 
whom the muscle cross-sectional area 
measurements were made 28 patients were 
defined as sarcopenic.
According to the NRS-2002 method, 32 out of 
77 patients were defined to be at nutritional risk, 
whereas only 26 out of the 77 were defined as 
malnourished by means of the SGA method.
Data for energy intake were missing in three 
patients and for CRP in one patient. In the 
remaining 73 patients, 16 were defined as 
having cachexia according to the CCSG criteria.
The EPCRC’s definitions of cachexia were 
possible to apply in 75 patients, and 41 of them 
were defined as having cachexia.
As seen in Table 2, having cachexia, defined 
by the CCSG criteria, increases the risk of death 
to 2.43 (2.26) in the unadjusted (adjusted) 
analysis. The single items weight loss and CRP 
had significant prognostic value in the 
unadjusted analysis, as well as cachexia defined 
by EPCRC. The changes in hazard ratio for all 
nutritional variables were minor after adjusting 
for covariates.
Table 1a. Clinical baseline data of all patients (N = 77)
Norway
N
Canada
N
50 27
Male/Female 26 / 24 15 / 12
Diagnosis
Ca. coli 27 20
Ca. recti 23 7
Radiation pre-surgery
Yes 5 7
No 45 20
Surgery
Yes 43 22
No 7 5
Metastasis
Lymph nodes 11 2
Peritoneum 4 2
Liver 32 18
Lung 12 10
Brain 1 0
Carcinomatosis
(peritoneal/pleural)
5 0
Skeletal 1 1
Other 2 3
Metastasis
One organ 31 19
Two organs 15 4
Three or more 
organs
4 4
WHO performance status
0
1
2
16
27
7
15
9
3
Intended to be treated 
with chemotherapy
Yes 48 18
No 2 9
Table 1b. Nutritional and blood parameters of all patients (N = 77)
Norway Canada
N N
50 27
Nutritional characteristics
Height (m), mean (SD) 1.72 (0.08) 1.69 (0.08)
Weight (kg), mean (SD) 74.1 (12.6) 80.1 (23.2)
BMI (kg/m2), mean (SD) 25.1 (3.5) 27.9 (7.4)
Nutritional intake
Energy intake, kcal, median (range) 1792¤ (639-2902) 2352 (1119-3870)
Energy intake, EI/BMR**, 
median (range)
1.31¤ (0.47-2.09) 1.46 (0.89-2.32)
Energy intake, kcal/kg median 
(range)
25.9¤ (9-42) 28.5 (14-55)
Blood analyses
Hb (g/L), median (range) 13.0 (8.5-15.7) 12.8 (9.4-15.4)
CRP (mg/L), median (range) 5.0 (<5-136) 4.2 (<1-18)
Albumin (g/L), median (range) 40 (29-47) 37 (23-43)
¤n=47, three of the Norwegian patients did not fill in the food diary.
** Energy intake, EI/Basal metabolic rate, BMR
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Table 3 shows the relation between BMI and 
sarcopenia in those 49 patients in whom the CT 
images at the L3 level were prepared within 30 
days from study baseline. Mean BMI of patients 
with sarcopenia was 22.4 kg/m2. In patients 
without sarcopenia (p=0.001) it was 27.5 kg/m2.
Rather surprisingly, two patients with BMI > 25 
kg/m2 were considered to have sarcopenia.
Table 3. Relation between BMI classes and 
sarcopenia in patients with colorectal 
carcinoma stage IV (N = 49#)
Sarcopenia
BMI Yes No
<18.5 2 0
18.6-19.9 2 1
20-24.9 11 10
25-29.9 2 10
>30 0 11
#Number of patients with CT images within 30 
days from baseline, p<0.001 (Mann–Whitney 
U test).
Overlaps between the various assessments 
are shown in Figure 1. Out of 73 patients, 32 
(44%) showed no nutritional decline by any of 
the methods used. Only nine patients were 
identified as nutritionally deranged by means 
of all the various assessments. The lack of 
concordance between the results obtained by 
means of the different nutritional assessment 
tools was striking. With the NRS-2002
method, quite a large number of patients (14) 
were identified as having nutritional risk 
whereas none of the other two methods used 
were able to detect these patients. Almost all 
of the 16 cachectic patients defined according 
to the CCSG criteria (CRP >10 mg/L, weight 
loss >10%, or a dietary intake <1500 kcal/d) 
were identified by means of the NRS-2002 or 
by the SGA methods. However, four patients 
with these rather obvious indices of 
malnutrition were not identified by means of 
the SGA criteria.
The overlaps between sarcopenia, SGA, and 
cachexia (CCSG), are shown in Figure 2 for 
those 49 patients in whom the CT images at 
the L3 level were taken within 30 days from 
study baseline. Notably, eight patients 
classified as sarcopenic were not identified as 
being malnourished or as having cachexia.
Overall survival according to the presence or 
absence of sarcopenia, nutritional risk (NRS-
2002), malnutrition (SGA), CCSG cachexia, and 
EPCRC cachexia is shown in Figs 3 a-e. Median 
survival for patients in the non-sarcopenia and that 
for the sarcopenia group were 17.3 and 15.3 
months, respectively (Log rank test, p=0.058). 
Median survival for patients with the absence or 
presence of nutritional risk (NRS-2002) was 19.1 
and 15.8 months, respectively (Log rank test, 
p=0.095). Statistically, there were no significant 
differences in survival between the patients in the 
SGA-groups A, B and C. Median survival for 
patients belonging to the  SGA-A group was 19.5, 
compared to 12.4 months in the SGA-B and C 
groups (Log rank test, p=0.055). There was a 
significant difference in survival in favour of the 
group without cachexia (CCSG) with a median 
survival of 21.4, compared to 13.3 months in the 
group with cachexia (Log rank test, p=0.003).  
Median survival for the patients defined according 
to cachexia (EPCRC) was 19.5 months without 
cachexia, compared to 15.8 months with cachexia 
(Log rank test, p=0.043).
4. Discussion
Patients with malignant neoplastic diseases are 
considered at risk for sarcopenia, malnutrition, and 
cachexia. Owing to the lack of a clear-cut concept 
of the criteria defining these conditions in cancer 
patients, different nutritional assessment tools 
have been used. In the present study, the results 
obtained by means of these assessment tools in a 
relatively homogenous group of patients reveal a 
high degree of inconsistency in the classification 
of nutritional decline of individual patients.
Sarcopenia
The prevalence of sarcopenia was high and 
sarcopenia was found in all BMI classes except the 
obese ones. Five times more patients were 
overweight/obese than underweight. The normal
and overweight/obese patients may appear well 
nourished despite loss of significant amount of 
body weight or muscle mass. In earlier studies, the 
prevalence of sarcopenia in overweight/obese 
patients with advanced pancreatic carcinoma, and 
in a mixed group of patients with lung and 
colorectal carcinomas is reported to be present in 
16% and 22%, respectively.14, 21 In the present 
study, only two out of 23 overweight patients had

Fig. 3a. Overall survival of patients with colorectal 
carcinoma stage IV (N=71) with respect to the 
presence (dotted line, N=28) or absence (solid line, 
N=43) of sarcopenia.
Fig. 3b. Overall survival of patients with 
colorectal carcinoma stage IV (N=77) with respect 
to the presence (dotted line, N=32) or absence 
(solid line, N=45) of nutritional risk (NRS-2002).
Fig. 3c. Overall survival of patients with colorectal 
carcinoma stage IV (N=77) with respect to the 
presence (dotted line, N=26) or absence (solid line, 
N=51) of malnutrition (SGA).
Fig. 3d. Overall survival of patients with 
colorectal carcinoma stage IV (N=73) with 
respect to the presence (dotted line, N=16) or 
absence (solid line, N=57) of cachexia 
defined by the Cancer Cachexia Study 
Group.
Fig. 3e. Overall survival of patients with 
colorectal carcinoma stage IV (N=75) with 
respect to the presence (dotted line, N=41) or 
absence (solid line, N=34) of cachexia 
defined by the European Palliative Care 
Research Collaborative.
signs of sarcopenia. The prevalence of 
sarcopenia in patients with different malignant 
neoplastic diseases has not been thoroughly 
investigated so far.
There was almost statistical significance for 
reduced survival in the patients with 
sarcopenia and the hazard ratio was similar to 
that found for SGA in the unadjusted analysis. 
The importance of sarcopenia for survival has 
until now mainly been studied in older people 
in whom muscle mass decrease has been 
related to functional impairment and loss of 
autonomy.22 In cancer patients, diagnostic and 
follow-up CT images can be used to assess the 
occurrence of sarcopenia and to establish its 
importance for survival. It is important to point 
out that sarcopenia in the present study was 
found in 8 patients who did not have cachexia 
or malnutrition. 
The aetiology of sarcopenia is 
multifactorial.23 Whether, or not sarcopenia is 
a result of immobilization and reduced 
physical activity or a consequence of 
metabolic components is a question that still 
remains unanswered.
NRS-2002
The NRS-2002 identified 42% of the patients 
to be at nutritional risk. Almost half of them 
were not identified as being malnourished by 
SGA and did not fulfil the criteria for cachexia 
(CCSG). The NRS-2002 considers patients at 
risk when the score is 3 or higher. Patients 
with an advanced malignant disease will easily 
accumulate 3 points; one point for the presence 
of cancer, one for age >70 years, and one for 
weight loss. As surgery is often the primary 
treatment in colorectal carcinoma it is 
probably the reason for some weight loss as 
well. Actually, in this group of patients, NRS-
2002 may identify a falsely large proportion of 
patients at nutritional risk and seems, 
therefore, to be less useful for nutritional 
screening.
According to the Venn-diagram, NRS-2002
was missing patients which by SGA were 
identified as malnourished. Although, SGA 
may not represent a golden standard, it has 
been previously found to have both high 
sensitivity and specificity when evaluated 
against objective nutritional variables.5
SGA
In this study about one third of the patients 
were classified as malnourished according to 
the SGA. To the best of our knowledge, this is 
the first study made on a fairly homogeneous 
group of patients with stage IV colorectal 
carcinoma. Nutritional status measured 
preoperatively in patients with colorectal 
carcinoma with different stages of the disease 
revealed 41% of the patients as malnourished 
according to SGA.24 Here, only 8% of the 
patients were at stage IV. Another study of 
colorectal carcinoma patients prior to 
radiotherapy showed a prevalence of 38% 
malnutrition assessed by the SGA tool.25 In the 
present study, 59% of the patients were at 
stage III/IV. Despite different stages of the 
disease and different oncological treatments, a 
prevalence of malnutrition of 30-40% must be 
considered to be quite substantial.
Cachexia
The CCSG definition of cachexia is one of 
several proposals in this field. It was 
introduced in a study of patients with 
pancreatic carcinoma in which cachexia was 
found to be related to the patients´ survival.12
In that study, 60% of the patients had cachexia. 
HR for overall survival was 2.23, a HR value 
close to that of our findings. These 
observations suggest that the CCSG definition 
of cachexia used should be applicable also in 
advanced colorectal carcinoma. According to 
the EPCRC’s newly published definition and 
classification of cancer cachexia16 a greater 
number of our patients were classified as 
having cachexia. As mentioned above, by 
means of the EPCRC’s criteria, cachexia is 
diagnosed with weight loss >5% over the past 
6 months or any degree of weight loss >2%, 
and BMI <20 or an appendicular skeletal 
muscle index consistent with sarcopenia. Using 
these EPCRC criteria, the prevalence of 
cachexia in the present study was found to be 
more than 50%, because as much as 39 of them 
had a weight loss of > 5%. As a matter of fact, 
20 of these patients were classified as well-
nourished by means of the SGA criteria and 
had stabilized or gained weight during the last 
month before baseline. 
Another aspect is the use of CRP as a 
criterion for cachexia. EPCRC’s criteria do not 
include CRP in the definition of cachexia, 
obviously due to the fact that cachexia can 
exist without overt systemic inflammation.16
CRP can be elevated for reasons other than 
cachexia; its levels can rise dramatically during 
an inflammatory process in the body. The 
patients in our study, recruited from outpatient 
clinics, showed a rather good performance 
status. Their elevated CRP probably is caused 
by the malignant disease itself and not by an 
incidental infection. Therefore, CRP may be a 
relevant parameter in cachexia. Having 
cachexia (CCSG definition) was the only 
variable that reached statistical significance in 
both unadjusted and adjusted survival analyses 
and was the most powerful predictor of 
survival in this study.
The patients included showed also, as 
expected, a highly functional performance 
status according to the WHO criteria. As we
did not perform an analysis of the patients 
excluded, there could be a selection bias. 
Patients who reject participation in studies 
have been shown to be older and more 
seriously ill.26 The prevalence of malnutrition 
is reported to be higher in patients of advanced 
age.27 Therefore, the occurrence of nutritional 
decline in an unselected cohort of patients with 
metastatic colorectal carcinoma may also be 
higher. Thus, the results should not be 
generalized applicable to an unselected 
population of patients with advanced 
colorectal carcinoma. 
The observed lack of concordance among 
the different nutritional assessment tools used 
in the present study highlights the need for 
more specific nutritional assessment tools for 
screening of patients with malignant neoplastic 
disease. A high proportion of the patients were 
identified by one tool only. It can be argued 
that a combination of CCSG cachexia and 
SGA can be a possible tool since both 
remained significant after adjusting for 
covariates. An important task will also be to 
investigate how the results obtained by such 
assessment tools can be linked to a nutritional 
intervention.
The different nutritional assessment tools 
were compared with regard to the patients 
overall survival. Since the majority of them 
received chemotherapy, it can be claimed that 
the survival data obtained have been 
influenced by treatment response, a possibility 
which has not been investigated in the present 
study. It has previously been shown that 
patients with weight loss at the time of 
initiating chemotherapy receive lower 
chemotherapy doses, develop more severe 
toxicity, and receive less antineoplastic 
treatment.28 Therefor, the reduced survival in 
nutritionally depleted patients shown in the 
present study may be associated with a lack of 
treatment response. 
In conclusion, the results of the present study 
show a high prevalence of sarcopenia, 
malnutrition, and cachexia among patients 
with advanced colorectal carcinoma and a lack 
of concordance between the nutritional 
assessments tools used. However, using the 
CCSG cachexia criteria, a group of patients 
with short survival was significantly 
distinguished.
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